EP2787992A1 - Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists - Google Patents

Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists

Info

Publication number
EP2787992A1
EP2787992A1 EP12806104.1A EP12806104A EP2787992A1 EP 2787992 A1 EP2787992 A1 EP 2787992A1 EP 12806104 A EP12806104 A EP 12806104A EP 2787992 A1 EP2787992 A1 EP 2787992A1
Authority
EP
European Patent Office
Prior art keywords
methyl
dioxo
amino
benzyl
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12806104.1A
Other languages
German (de)
French (fr)
Other versions
EP2787992B1 (en
Inventor
Imre Bata
Péter BUDZER-LANTOS
Attila Vasas
Veronika BARTÁNÉ BODOR
György FERENCZY
Zsuzsanna TÖMÖSKÖZI
Gábor SZELECZKY
Sándor BÁTORI
Martin Smrcina
Marcel Patek
Aleksandra Weichsel
David S.THORPE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to EP12806104.1A priority Critical patent/EP2787992B1/en
Publication of EP2787992A1 publication Critical patent/EP2787992A1/en
Application granted granted Critical
Publication of EP2787992B1 publication Critical patent/EP2787992B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C07D207/408—Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/20—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with no nitrogen atoms directly attached to a ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to compounds that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines.
  • Chemokines are a large family of small soluble proteins of about 8 to 10 kDa in size.
  • One of the major roles of chemokines is to direct the migration of immune cells. The mechanism by which the movement of cells is guided is the chemical attraction of the cells expressing the relevant chemokine receptor on their surface toward the concentration gradient of the corresponding chemokine.
  • Some chemokines are homeostatic in function as they regulate the trafficking of cells in a day to day manner. Such homeostatic chemokines, for example direct the homing of lymphocytes to the lymph nodes or they have effect on development by promoting or inhibiting the growth of new blood vessels - thus exerting angiogenic or angiostatic effects.
  • chemokines are expressed in response to inflammation or injury. These inflammatory chemokines regulate the recruitment of specific leukocyte populations into the inflamed tissue that in turn they can elicit the release of specific regulatory and enzymatic factors from the activated immune cells. The expression of these inflammatory chemokines is typically induced by interleukin-1 (IL-1) or interferon- ⁇ (IFN- ⁇ ) from various types of cells.
  • IL-1 interleukin-1
  • IFN- ⁇ interferon- ⁇
  • Chemokines exert their function via binding to specific chemokine receptors that are expressed on the cell surface.
  • the chemokine receptors are about 340-360 amino acids long, and they belong to the G-protein coupled receptor (GPCR) super family.
  • GPCR G-protein coupled receptor
  • approximately 50 chemokines have been identified. Many of them can bind to the same receptor and particular chemokines can also bind to several chemokine receptors.
  • Presently we know altogether 20 different chemokine receptors for these 50 known chemokines [Groom, J.R. and Luster, A.D. 2011. Immunology and Cell Biology, 1-9]. More recently different splice variants have also been described for some chemokine receptors that may have different expression patterns and different physiological or pathophysiological roles.
  • CXCR3 is an inflammatory chemokine receptor which is predominantly expressed on activated immune cells such as the CD4 + (Thl helper) and CD8 + (CTL cytotoxic or Tc) T lymphocytes.
  • CXCR3 is absent on naive T lymphocytes, but its cell surface expression is rapidly induced following T cell activation by dendritic cells.
  • CXCR3 is also expressed on innate lymphocytes such as natural killer cells (NK) and NKT cells, on plasmacytoid dendritic cells (pDC) [Groom, J.R. and Luster, A.D. 201 1. Immunology and Cell Biology, 1-9], on inflammatory neutrophils and macrophages.
  • CXCR3 is selectively activated by three interferon-inducible chemokines, CXCL9 (also termed as Mig), CXCL10 (IP- 10) and CXCL11 (I-TAC). Activation of CXCR3 by these endogenous agonists elicits intracellular Ca 2+ mobilization via phospholipases C (PLC) and, in addition, activation of both mitogen-activated protein kinase (MAP-kinase) and PI3-kinase [Liu, M; Guo, S; Hibbert, J.M; Jain, V; Sinh, N Wilson, N.O; and Stiles, J.K. 201 1.
  • MAP-kinase mitogen-activated protein kinase
  • PI3-kinase PI3-kinase
  • CXCR3 Cytokine & Growth Factor Reviews, 22: 121-130.]. These intracellular events finally result in stimulation of lymphocyte migration and proliferation.
  • CXCR3 plays a key role in selective recruitment of activated immune cells to the site of inflammation. Once recruited, cytotoxic T cells (CTL), through the release of perforin and granzyme B, induce apoptosis, thereby contributing to local tissue damage and subsequent remodelling. At the site of inflammation the recruited Thl and CTL cells release IFN-gamma that stimulates epithelial cells and macrophages to further release of CXCR3 agonists that leads to a persistent inflammatory activation.
  • CTL cytotoxic T cells
  • IFN-gamma IFN-gamma that stimulates epithelial cells and macrophages to further release of CXCR3 agonists that leads to a persistent inflammatory activation.
  • Treg human CD25+ FOXP3+ regulatory CD4+ T cells
  • CXCR3 may participate in mediation of trafficking of Treg cells.
  • Treg cells migrate to the peripheral sites of inflammation, where they exert suppressive activity on CD4+ Thl and CD8+ CTL cells [Hoerning, A et al 2011. Eur J Immunol, online manuscript, accepted: April 26, 201 1. DOI: 10.1002/ej i .201041095] .
  • Treg cells are important for suppressing the immune responses, maintaining immune tolerance and preventing autoimmune responses.
  • CXCR3-A As of today, there are three splice variants for CXCR3 described in humans: CXCR3-A,
  • CXCR3-B [Romagnani, P; Lasagni, L; Annunziato, F; Serio, M. and Romagnani, S. 2004. TRENDS in Immunology, 25: 201-209.] and CXCR3-alt.
  • CXCR3-A is the most abundant variant, it couples to Gi/o type of G-proteins and it mediates chemotaxis and cell proliferation.
  • CXCR3-B The splice variant CXCR3-B is thought to be expressed on endothelial and vascular smooth muscle cells and mediates angiostatic effects [Strieter, R.M; Burdick, M.D; Gomperts, B.N; Belperio, .A; Keane, MP. 201 1. Cytokine & Growth Factor Reviews 16:593-609.].
  • CXCR3-B can bind not only the three well known CXCR3 agonists, CXCL9 (Mig), CXCL10 (IP-10) and CXCLl l (I-TAC). but also a forth one, CXCL4 (PF-4), which is a selective, CXCR3-B specific chemokine agonist.
  • CXCR3-B Activation of CXCR3-B is supposed to mediate the activation of the Gs, the stimulatory type of G-proteins that in turn causes an intracellular cAMP rise, which finally results in angiostatic effects and inhibition of cell proliferation.
  • the alternative CXCR3-B splice variant does not exist in mice [Campanella, G.S.V; Colvin, R.A; and Luster, A.D. 2010. PLoS ONE 5(9): el2700. doi: 10.1371/journal.pone.0012700] and, in addition to it, the same authors in their experiments with human endothelial cells also demonstrated that CXCL10 can inhibit endothelial cell proliferation independently of CXCR3 receptors.
  • CXCL10 can inhibit endothelial cell proliferation independently of CXCR3 receptors.
  • T lymphocytes play crucial regulatory function in the immune system [Wijtmans, M; Verzijl, D; Leurs, R; de Esch, I.J.P; and Smit, M.J. 2008. ChemMedChem. 3:861-872.] and [Muller, M; Carter, M.J; Hofert, J; and Campbell, I.L. 2010. Neuropathology and Applied Neurobiology, 36:368-387.]. Their special roles are also indicated by the fact that 15 chemokine receptors out of the 20 known ones, are expressed among the different subpopulations of T lymphocytes [Pease and Williams, Br. J. Pharmacol. 2006. 147, S212]. T cells are implicated in many inflammatory diseases. Clinical evidences showed significant overexpression of CXCR3 receptor and/or its endogenous agonists (CXCL10, CXCL1 1) in multiple autoimmune or inflammatory diseases, such as e.g.
  • CXCR3-KO mice display blocked T cell migration into bronchoalveolar space following noxious stimuli such as cigarette smoke (murine model of COPD).
  • CXCLlO-gene deficient or CXCR3-KO mice showed prolonged allograft survival in murine models of transplant rejection (cardiac and pancreatic island allografts).
  • Blocking the activation of CXCR3 by antagonists represents a possible approach for the treatment of diseases such as COPD [Hansel, T.T. and Barnes, P.J. 2009. Lancet, 374:744-755], psoriasis [Krueger, J.G. and Bowcock, A. 2005. Ann. Rheum. Dis. 64: Suppl.IL: ii30-ii36.], graft/transplant rejection [Hancock, W.W; Lu, B; Gao, W; Cziszmadia, V; Faia, K; King, J.A; Smileey, S.T; Ling, M; Gearad, N.P; and Gerard, C. 2000.
  • Targeting CXCR3 appears a more straightforward way to treat the condition as this abrogates the effects of all three endogenous CXCR3 chemokines at the same time.
  • R 3 represents hydrogen, halogen, CF 3 , CN or Ci -4 alkyl
  • R 4 represents hydrogen, halogen or C 1-4 alkyl-
  • X represents a C 2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a heteroatom selected from O and S, or -CH(CH 2 )CH-;
  • Z represents a C aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, NH and N(CH 3 ) or represents a C 2-4 aliphatic hydrocarbon bridge fused with a C 3 . 6 cycloalkyl ring optionally containing one or more double bond or with a phenyl ring or represents a CM aliphatic hydrocarbon bridge substituted with a spiro C 3-6 cycloalkyl ring optionally containing one or more double bond;
  • a process for the preparation of a compound of formula 1 or a pharmaceutically acceptable salt, stereoisomer or a pharmaceutically acceptable salt of the stereoisomer comprising the steps of reductive amination of a benzaldehyde of formula 4
  • the present invention is directed to the compounds of formula 1 or a pharmaceutically acceptable salt, stereoisomer or a pharmaceutically acceptable salt of the stereoisomer for use in the preventive and/or therapeutic treatment of a CXCR3 receptor mediated disease or disorder, especially of a disease or disorder selected from the group consisting of COPD, psoriasis, graft/transplant rejection, ophthalmological disease, celiac disease, inflammatory bowel disease (IBD), type 1 diabetes, myasthenia gravis (MG), multiple sclerosis (MS) and other neuroinfiammatory diseases, lupus, rheumatoid arthritis (RA) or lichen planus.
  • a disease or disorder selected from the group consisting of COPD, psoriasis, graft/transplant rejection, ophthalmological disease, celiac disease, inflammatory bowel disease (IBD), type 1 diabetes, myasthenia gravis (MG), multiple sclerosis (MS) and other neuroinfia
  • the Ci -4 hydroxyalkyl group represents an above indentified alkyl group having 1 to 4 carbon atoms and bearing one or more hydroxy group, for example, hydro xymethyl group, 1- hydroxy-ethyl group, 2- hydroxy-ethyl group, 1 -, 2- or 3- hydroxy- n-propyl group, 1 - or 2- hydroxy-isopropyl group, and the like.
  • the halogen atom represents a fluorine, chlorine, bromine or iodine atom.
  • the C aliphatic hydrocarbon bridge substituted with a spiro C 3-6 cycloalkyl ring optionally containing one or more double bond means an alkandiyl group having 1 to 4 carbon atoms and substituted with a spiro cycloalkyl ring having 3 to 6 carbon atoms and optionally
  • the compounds of formula 1 can also exist in the form of cis (Z) or trans (E) stereoisomers. These stereoisomers, enantiomers and diastereoisomers as well as their mixtures, including the racemates, are also subject of the invention.
  • One of the embodiments of the present invention includes compounds of formula 1 wherein
  • R represents hydrogen or Cj.4 alky 1
  • R 2 represents hydrogen or C 1-4 alkyl
  • R 4 represents hydrogen, halogen or Ci -4 alkyl
  • Y represents hydrogen, halogen; C 1-4 alkyl, C 1-4 alkoxy or C 1-4 hydroxyalkyl;
  • Another embodiment of the present invention includes compounds of formula 1 wherein 1 represents a group selected from the group consisting of
  • R 4 represents hydrogen, CI, F or methyl
  • R 2 represents methyl or ethyl
  • R 4 represents hydrogen, CI or F
  • R 1 represents a group selected from the group consisting of wherein R 2 represents methyl or ethyl
  • R 4 represents hydrogen, CI or F
  • Another embodiment of the present invention includes compounds of formula 1 wherein
  • Another embodiment of the present invention includes compounds of formula 1 wherein
  • Y represents ethyl or methoxy; or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
  • Another embodiment of the present invention includes compounds of formula 1 wherein
  • Z represents -(CH 2 ) 2 - or -CH 2 -N(CH 3 )-; or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
  • R represents hydrogen, methyl or ethyl; R 1 represents a group selected from the
  • R represents hydrogen methyl or ethyl
  • R 3 represents hydrogen, chloro, fluoro, CF 3 , CN, methyl or ethyl
  • R c and R represent independently from each other H or methyl or ethyl
  • Y represents chloro, fluoro, methyl, ethyl, methoxy or -CH 2 -OH;
  • a particular group of the compounds of the present invention represented by formula 1 include compounds selected from the group consisting of:
  • a further embodiment of the invention includes compounds of formula 4,
  • X represents a C 2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a heteroatom selected from O and S, or -CH(CH 2 )CH-;
  • Y represents hydrogen, halogen, C alkyl, C 1-4 alkoxy or Ci- hydroxyalkyl
  • Z represents a C
  • Particularly compounds represented by formula 4 include compounds selected from the group consisting of
  • a further embodiment of the invention includes compounds of formula 2
  • R 2 represents hydrogen or C 1-4 alkyl group
  • R 3 represents hydrogen, halogen, CF 3 , CN or Q. 4 alkyl; and R 4 represents hydrogen, halogen or C ] -4 alkyl;
  • X represents a C 2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a heteroatom selected from O and S, or -CH(CH 2 )CH-;
  • Y represents hydrogen, halogen, Ci -4 alkyl, C 1-4 alkoxy or C 1-4 hydroxyalkyl
  • Z represents a Ci -4 aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, N and N(CH 3 ) or represents a C 2-4 aliphatic hydrocarbon bridge fused with a C 3 . 6 cycloalkyl ring optionally containing one or more double bond or with a phenyl ring or represents a Ci -4 aliphatic hydrocarbon bridge substituted with a spiro C 3-6 cycloalkyl ring optionally containing one or more double bond;
  • Particularly compounds represented by formula 2 include compounds selected from the group consisting of
  • the crude product is purified by column chromatography or flash chromatography.
  • benzaldehydes 4 are reacted with different primary amines 5 in mild reductive amination conditions (NaBH(OAc) 3 in THF or 2-picoline borane complex in EtOH).
  • the crude 1 is purified by chromatography, crystallization or via salt formation (Scheme 2).
  • Starting materials of formula 3, 5 and 7 are commercially available or can be prepared by known methods.
  • Compounds of formula 6 are commercially available (6a) or can be prepared by known methods.
  • Compounds of formula 6b can be synthesized with tryflation of the corresponding alcohol.
  • a compound of formula 6c is a protected derivative of an aldehyde of formula 6a with ethyleneglycol.
  • a compound of formula 6d can be synthesized from commercially available benzoic acid derivatives by known method (Scheme 3).
  • the compounds of formula 1 or a pharmaceutically acceptable salt, stereoisomer or a pharmaceutically acceptable salt of the stereoisomer can be used as active ingredient of a medicament in the preventive and/or therapeutic treatment of a CXCR3 receptor mediated disease or disorder, especially of a disease or disorder selected from the group consisting of COPD, psoriasis, graft/transplant rejection, ophthalmological disease, celiac disease, inflammatory bowel disease (IBD), type 1 diabetes, myasthenia gravis (MG), multiple sclerosis (MS) and other neuroinflammatory diseases, lupus, rheumatoid arthritis (RA) or lichen planus.
  • a CXCR3 receptor mediated disease or disorder especially of a disease or disorder selected from the group consisting of COPD, psoriasis, graft/transplant rejection, ophthalmological disease, celiac disease, inflammatory bowel disease (IBD), type 1 diabetes, myasthenia gravis (MG), multiple s
  • a substance may be used which is selected from the group consisting of the compound represented by the aforementioned formula 1 and pharmacologically acceptable salts, or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
  • the substance, per se, may be administered as the medicament of the present invention, however, it is desirable to administer the medicament in a form of a pharmaceutical composition which comprises the aforementioned substance as an active ingredient and one or more pharmaceutical additives.
  • the active ingredient of the medicament of the present invention two or more of the aforementioned substances may be used in combination.
  • the type of pharmaceutical composition is not particularly limited, and the composition may be provided as any formulation for oral or parenteral administration.
  • the pharmaceutical composition may be formulated, for example, in the form of pharmaceutical compositions for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, solutions and the like, or in the form of pharmaceutical compositions for parenteral administrations such as injections for intravenous, intramuscular, or subcutaneous administration, drip infusions, transdermal preparations, transmucosal preparations, nasal drops, inhalants, suppositories and the like. Injections or drip infusions may be prepared as powdery preparations such as in the form of lyophilized preparations, and may be used by dissolving just before use in an appropriate aqueous medium such as physiological saline.
  • pharmaceutical compositions for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, solutions and the like
  • parenteral administrations such as injections for intravenous
  • Types of pharmaceutical additives used for the manufacture of the pharmaceutical composition, content ratios of the pharmaceutical additives relative to the active ingredient, and methods for preparing the pharmaceutical composition may be appropriately chosen by those skilled in the art.
  • Inorganic or organic substances, or solid or liquid substances may be used as pharmaceutical additives.
  • the pharmaceutical additives may be incorporated in a ratio ranging from 1 % by weight to 90% by weight based on the weight of an active ingredient.
  • the dose and frequency of administration of the medicament of the present invention are not particularly limited, and they may be appropriately chosen depending on conditions such as a purpose of preventive and/or therapeutic treatment, a type of a disease, the body weight or age of a patient, severity of a disease and the like.
  • a daily dose for oral administration to an adult may be 0.01 to 1 ,000 mg (the weight of an active ingredient), and the dose may be administered once a day or several times a day as divided portions, or once in several days.
  • administrations may preferably be performed continuously or intermittently in a daily dose of 0.001 to 100 mg (the weight of an active ingredient) to an adult.
  • Diazald N-methyl-N-nitroso-p-toluenesulfonamide
  • K P0 4 potassium phosphate
  • MEK methyl -ethyl ketone
  • Na 2 S0 4 sodium sulfate
  • NaBH(OAc) 3 sodium triacetoxy borohydride
  • TBAB tetrabutylammonium bromide
  • TsOH p-toluenesulfonic acid monohydrate
  • MS Waters LCT Premier XE; Column: Atlantis dC 18 (3 ⁇ ) 2.1x50mm; flow 0.7 ml/min of acetonitrile/water/0.05% TFA gradient in ESI+ mode
  • MS Micromass ZQ; Column: Purospher-STAR RP18e (3 ⁇ ) 4.6x55mm; flow 1.6 ml/min of water/acetonitril/20mM NH 4 OH gradient or Xterra MS-C18 (3.5 ⁇ ) 2.1x50mm; flow: 1.0 ml/min of water/acetonitril/20mM NH 4 OH gradient in ESI+ mode.
  • NMR spectra are recorded on a Bruker Advance II 400 MHz spectrometer at ambient temperature in DMSO- 6 solution. The chemical shifts are referred to tetramethylsilane ( ⁇ , ppm). In some cases not only ⁇ but 13 C, ed-HSQC, zqs-TOCSY and HMBC spectra are also recorded. Precursor preparations
  • Step 1 6.85 g (45 mmol) vanilline (6.1) is cooled in a 100 ml of a mixture of DCM- pyridine 4:1, then 9.1 ml (54 mmol) of trifluoromethanesulfonic anhydride in 10 ml DCM is dropped in. The mixture is stirred at r.t. for 2 hours, after evaporated and the residue is triturated with 3 x 10 ml of EtOAc, the collected organic layer is dried and evaporated. The crude material (6.1a) is used for next step without further purification.
  • Step 3 A mixture of 1.76 g (5 mmol) triflate (6.1a), 2.1 g (15 mmol) of 1-allyl- pyrrolidine-2,5-dione (7.3; Bull.Chem. Soc. Japan, 1984, 57(10), 3021), 0.067 g (0.3 mmol) of Pd(OAc) 2 , 0.373 g (5 mmol) KC1, 3.22 g (10 mmol) TBAB and 2.12 g (10 mmol) K 3 P0 4 is hetaed in 10 ml DMF under nitrogen at 120°C for 8 h.
  • Diazomethane is generated with a diazomethane-generating kit (Aldrich): a solution of 3.846 g (17.9 mmol) of Diazald in 24 ml of Et 2 0 is added drop wise to a mixture of 3.018 g (53.78 mmol) of OH in 18 ml of water, 4 ml of diethyl ether and 18 ml of 2-(2-ethoxyethoxy)- ethanol at 70 °C.
  • Aldrich a solution of 3.846 g (17.9 mmol) of Diazald in 24 ml of Et 2 0 is added drop wise to a mixture of 3.018 g (53.78 mmol) of OH in 18 ml of water, 4 ml of diethyl ether and 18 ml of 2-(2-ethoxyethoxy)- ethanol at 70 °C.
  • Example 1 /rfl is-4-[([l-(2,3-Dihydro-l-benzofuran-5-yl)ethyl] ⁇ 4-[2-(2,5-dioxo-pyrrolidin- l-yI)ethoxy]-3-methoxybenzyl ⁇ amino)methyl]cyclohexanecarboxylic acid
  • Step 2 950 mg (2.24 mmol) of free amine (2.1) and 1.14 g (6.72 mmol) of trara-4-formyl- cyclohexanecarboxylic acid ethyl ester (3.1) are dissolved in THF and 0.19 mL (3.36 mmol) of AcOH is added followed by the addition 2.37 g (1 1.19 mmol) of NaHB(OAc) 3 and the reaction is stirred overnight at room temperature. Then the reaction is diluted EtOAc (75 ml) and water (50 ml) and 2 ml IN HC1 is added. The aqueous phase is separated, the organic phase is extracted two times with the same amounts of water and IN HC1 solution.
  • Step 1 is undertaking as in Example 1, step 2 is accomplished with cw-4-formyl- cyclohexanecarboxylic acid methyl ester (3.2) in same conditions, after acidic hydrolysis and purification the title compound is isolated as a white foam.
  • Example 5 i -a «s-4-[([(S)-l-(4-Chloro-phenyl)-ethyl]- ⁇ 4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methoxy-benzyl ⁇ -amino)-methyl]-cyclohexanecarboxylic acid
  • Step 1 is undertaking as in Example 1 using (5)-l-(4-chloro-phenyl)-ethylamine (5.2), further steps are occurred analogously as in Example 1 and the desired compound is resulted.
  • Example 6 // • a is-4-[([(R)-l-(4-Chloro-phenyl)-ethyl]- ⁇ 4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methoxy-benzyl ⁇ -amino)-methyl]-cyclohexanecarboxylic acid
  • Step 1 is undertaking as in Example 5 using ( ?)-l-(4-chloro-phenyl)-ethylamine (5.3), further steps are occurred analogously as in Example 1 and the desired compound is resulted.
  • Example 7 /r is-4-[([(S)-l-(4-Chloro-phenyl)-ethyl]- ⁇ 4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methyl-benzyI ⁇ -amino)-methyl]-cyclohexanecarboxylic acid
  • Step 1 is undertaking as in Example 1 using (S)-l-(4-chloro-phenyl)-ethylamine (5.2) and Intermediate 4.2, further steps are occurred analogously as in Example 1 and the desired compound is resulted.
  • Step 1 is undertaking as in Example 7, step 2 is accomplished with cw-4-f rmyl- cyclohexanecarboxylic acid methyl ester (3.2) in same conditions, after acidic hydrolysis and purification the title compound is isolated.
  • Step 1 is undertaking as in Example 6 using (/?)-l -(4-chloro-phenyl)-ethylamine (5.3) and Intermediate 4.2, further steps are occurred analogously as in Example 6 and the desired compound is resulted.
  • Example 10 // • a «s-4-[((5-Chloro-indan-l-yl)- ⁇ 4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl ⁇ -amino)-methyl]-cyclohexane-carboxylic acid
  • Example 11 ira «s , -4-[(((3 ⁇ 4! -5-ChIoro-indan-l-yl)- ⁇ 4-[2-(2,5-dioxo-pyrroIidin-l-yl)-ethoxy]- 3-methoxy-benzyI ⁇ -amino)-methyl]-cyclohexanecarboxylic acid
  • Example 14 /i-a «s-4-[(((5)-4,5-Dichloro-indan-l-yl)- ⁇ 4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methoxy-benzyl ⁇ -amino)-methyl]-cyclohexanecarboxylic acid hydrochloride
  • Step 1 and 2 3.70 g (15.5 mmol) of (S)-4,5-dichloro-indan-l-ylamine hydrochloride (5.6) is dissolved in DCM, washed with saturated sodium bicarbonate and brine, dried over sodium sulfate and evaporated at reduced pressure. The residue is dissolved in THF and placed into a water bath (bath temperature: 15°C). 4.29 g (15.5 mmol) of Intermediate 4.1 is added followed by the addition of acetic acid (1.33 ml; 23.3 mmol). 8.21 g (38.7 mmol) of NaBH(OAc) 3 is added in four portions at 10 minutes intervals. Water bath is removed and the reaction is stirred one hour at room temperature.
  • Step 1 0.37 g (2.24 mmol) of l-(2,3-dihydro-benzofuran-5-yl)-ethylamine (5.1) and 0.62 g (2.054 mmol) of Intermediate 4.13 are dissolved in 10 ml of THF. 0.17 ml (3.06 mmol) of AcOH and 1.08 g (5.09 mmol) of NaHB(OAc) 3 are added in and the reaction is stirred overnight. Then the mixture is diluted with water, pH adjusted to 8-9 with NaHC0 3 and it is extracted with EtOAc, the combined organic phase is washed water and brine, dried Na 2 S0 4 and evaporated. The intermediate of 2.2 is 0.88 g (95.6%).
  • Example 121 375 mg (0.68 mmol) of Example 121 is separated by preparative chiral column chromatography (Berger SFC systems; Chiralcel OJ-H 250x21 mm column (5 ⁇ ); 50 ml/min flow rate; C02/ 80%/20%; EtOH + 0.5% IP A).
  • the first eluted enantiomer has (/ ⁇ -configuration, yield is 124 mg (68%).
  • Example 121 375 mg (0.68 mmol) of Example 121 is separated by preparative chiral column chromatography (Berger SFC systems; Chiralcel OJ-H 250x21 mm column (5 ⁇ ); 50 ml/min flow rate; C02/ 80%/20%; EtOH + 0.5% IPA).
  • the second eluted enantiomer has (5)- configuration, yield is 125 mg (68%).
  • Example 124 /ra is-3-([l-(4-Chloro-3-fluoro-phenyl)-ethyl]- ⁇ 4-[2-(2,5-dioxo-pyrrolidin-l- yl)-ethoxy]-3-methyl-beniiyl ⁇ -amino)-cyclobutanecarboxylic acid
  • Step 1 is undertaking as in Example 120 using l-(4-chloro-3-fluoro-phenyl)-ethyl-amine (5.7) and (4.2) for the first reductive amination step.
  • CHO cells stably expressing human recombinant CXCR3-A receptors were generated in Sanofi-Aventis (LIT Frankfurt) by transfection of Flp-In-CHO host cells with a plasmid construct of pCDA5-FRT-TO_IRES-Gai4qi4_DEST. This cell line was registered in Sanofi-Aventis cell line bank.
  • Cells were grown in Ham's F12 (PAA) medium supplemented with 10% FCS (PAA, Cat No. El 5-898) and 0.6 % Hygromycin (PAA) in T175 flasks at 37°C in a humidified incubator under 5% CO 2, 95% air.
  • PAA Ham's F12
  • FCS PAA, Cat No. El 5-898
  • PAA Hygromycin
  • This suspension was homogenized with a teflon/glass homogenizer (Sartorius potter S) with 3 x 10 sec pulses in ice cold water bath, and then centrifuged at 300 x g for 10 min at 4°C with a Sigma centrifuge. The supernatant was carefully collected and centrifuged at 100,000 x g for 60 min at 4° with a Beckman Avanti J30 centrifuge. The resulting pellet was washed once with 15 ml of fresh preparation buffer.
  • a teflon/glass homogenizer Sudtorius potter S
  • Competition binding assay was performed using 125I-CXCL10 (PerkinElmer, NEX348, specific activity 2200 Ci/mmol) radioligand in a final concentration of 50-70 pM.
  • the nonspecific binding was defined by 150 pM of hr-CXCLlO (R&D Systems, Cat No 266-IP).
  • Binding reaction was initiated by adding of membranes (10-20 ⁇ g proteins, approximately 5 x 10 5 cell equivalents) to the reaction mixture. After 60 minutes of incubation at 25°C the reaction was terminated by rapid filtration over GF/B glass fibre filters that were pre-soaked with 0.5% poliethylenimine (Fluka Analytical, P3143) for 1 hour, using a Skatron cell harvester device. Filters then were washed with 8 ml of ice-cold wash buffer (modified binding buffer in which BSA was omitted and the concentration of NaCl was adjusted to 500 mM concentration). The radioactivity retained on the filters was measured by a Wizard 1470 Automatic Gamma counter.
  • Test compounds were dissolved prior to the binding assay at a concentration of 10 mM in
  • the exemplified compounds of the present invention have activities in the above binding assay of less than 20 micromolar, more particular compound have activities of less than 1 micromolar, and further particular compounds have activities of less than 200 nanomolar IC50.
  • Example # IC50 (nM) Example # IC50 (nM)
  • cyclic adenosine 3 ',5 '-monophosphate (cyclic AMP, or also called as cAMP) level following either stimulation or activation of CXCR3-A receptor was used to demonstrate the antagonistic functionality of the selected compounds.
  • Cyclic AMP is one of the most important intracellular second messenger molecules whose level is regulated principally by the G-protein coupled adenylyl cyclase effector enzyme located in the inner surface of the cellular plasma membrane. Receptor dependent, G-protein mediated changes in the cyclic AMP concentration elicit then complex regulatory processes within the cell such as activation of multiple protein kinases and phospholipases, generation of inositol triphosphate and transient rise in the intracellular calcium ion (Ca2+) concentration, ion channel gating, effects on different gene transcriptions.
  • Ca2+ calcium ion
  • CXCR3-A receptor Upon agonist stimulation, CXCR3-A receptor activates the pertussis toxin (PTX) sensitive G- proteins of the Gi class that mediates a reduction in the intracellular cAMP levels, an increase in the intracellular Ca2+ mobilization and actin polymerization, that finally lead to cytoskeletal rearrangement and directed cell migration (chemotaxis).
  • PTX pertussis toxin
  • Cyclic AMP accumulation assay was performed with a homogeneous time-resolved fluorescence (HTRF) cAMP femto 2 kit from CisBio International. The measurement was basically carried out by following the manufacturer's instructions.
  • HTRF time-resolved fluorescence
  • CXCR3-A receptor is coupled to Gi-protein, thus an agonist activation of the receptor will lead to a decrease in the intracellular cAMP level [Crosignani S. et al, 2010. Bioorg. Med. Chem Letters, 20:3614-3617]. Therefore, the cells have to be preactivated by forskolin, a direct activator of the cell adenylyl cyclase enzyme, in order to reach a sufficient cellular basal cAMP level.
  • the agonist induced decrease in cAMP level will be measured by an increase of the Fluorescence Resonance Energy Transfer signal, as the signal is inversely proportional to the concentration of cAMP in the cell.
  • the adherent hr-CXCR3-Flp-In-CHO- IRES-Gai4qi4 cells were washed with Ca2+-Mg2+ free PBS and harvested by a short treatment with Acutase (Sigma, A6964).
  • Acutase Sigma, A6964
  • 7 ml of culture medium was added to the detached cells.
  • Cell suspension was collected and centrifuged at 1,700 rpm for 10 min. (Sigma 2-S table centrifuge).
  • the resulting cell pellet was resuspended in PBS with Ca2+/Mg2+ (Invitrogen 14080-048) and subjecting to a second centrifugation step as above.
  • the final cell pellet was resuspended in assay buffer (PBS with Ca2+/Mg2+, supplemented with fatty acid free BSA (Sigma A6003) at a final concentration of 1 mg/ml and with the phosphodiesterase inhibitor Rolipram (Calbiochem 557330) at a final concentration of 10 ⁇ .
  • Cells were transferred to a 96- well microplate (Costar 3694, Half Area flat bottom, non-treated, black polystyrene plate) at a density of 16,000 cells/well.
  • the cells were incubated in the presence of different concentrations of antagonist compounds (within the range of 10 ⁇ and 0.1 nM) for 10 min at room temperature (R.T.) under continuous shaking the microplate in a plate shaker (Heidolph Titramax 100, at 600 rpm).
  • the final concentration of DMSO in reaction mixture was 0.1 %.
  • CXCLIO at a final concentration of 20 nM was added and the cells were further incubated for 10 min at R.T., as above.
  • forskolin Sigma F-6886
  • the final reaction volume was 40 ⁇ .
  • the reaction was stopped by adding the lysis buffer containing the HTRF reagents.
  • Delta F ( Standard or Sample Ratio - Negative Control Ratio)/ (Negative Control Ratio) x 100.
  • the negative control corresponded to the background signal obtained with the cryptate conjugate alone.
  • the compounds tested in the above functional cAMP assay displayed an IC50 value of less than 2 micromolar and particularly less than 20 nanomolar.
  • the compounds of the present invention have CXCR3 inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of a CXCR3 receptor mediated disease or disorder, especially of a disease or disorder selected from the group consisting of COPD, psoriasis, graft/transplant rejection, ophthalmological disease, celiac disease, inflammatory bowel disease (IBD), type 1 diabetes, myasthenia gravis (MG), multiple sclerosis (MS) and other neuroinflammatory diseases, lupus, rheumatoid arthritis (RA) or lichen planus.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

The present invention relates to compounds of formula 1 that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to the novel intermediates used in the preparation of said compounds.

Description

Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
The present invention relates to compounds that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines.
Chemokines are a large family of small soluble proteins of about 8 to 10 kDa in size. One of the major roles of chemokines is to direct the migration of immune cells. The mechanism by which the movement of cells is guided is the chemical attraction of the cells expressing the relevant chemokine receptor on their surface toward the concentration gradient of the corresponding chemokine.
Some chemokines are homeostatic in function as they regulate the trafficking of cells in a day to day manner. Such homeostatic chemokines, for example direct the homing of lymphocytes to the lymph nodes or they have effect on development by promoting or inhibiting the growth of new blood vessels - thus exerting angiogenic or angiostatic effects.
Other chemokines are expressed in response to inflammation or injury. These inflammatory chemokines regulate the recruitment of specific leukocyte populations into the inflamed tissue that in turn they can elicit the release of specific regulatory and enzymatic factors from the activated immune cells. The expression of these inflammatory chemokines is typically induced by interleukin-1 (IL-1) or interferon-γ (IFN-γ) from various types of cells.
Chemokines exert their function via binding to specific chemokine receptors that are expressed on the cell surface. The chemokine receptors are about 340-360 amino acids long, and they belong to the G-protein coupled receptor (GPCR) super family. To date, approximately 50 chemokines have been identified. Many of them can bind to the same receptor and particular chemokines can also bind to several chemokine receptors. Presently we know altogether 20 different chemokine receptors for these 50 known chemokines [Groom, J.R. and Luster, A.D. 2011. Immunology and Cell Biology, 1-9]. More recently different splice variants have also been described for some chemokine receptors that may have different expression patterns and different physiological or pathophysiological roles.
CXCR3 is an inflammatory chemokine receptor which is predominantly expressed on activated immune cells such as the CD4+ (Thl helper) and CD8+ (CTL cytotoxic or Tc) T lymphocytes. CXCR3 is absent on naive T lymphocytes, but its cell surface expression is rapidly induced following T cell activation by dendritic cells. CXCR3 is also expressed on innate lymphocytes such as natural killer cells (NK) and NKT cells, on plasmacytoid dendritic cells (pDC) [Groom, J.R. and Luster, A.D. 201 1. Immunology and Cell Biology, 1-9], on inflammatory neutrophils and macrophages.
CXCR3 is selectively activated by three interferon-inducible chemokines, CXCL9 (also termed as Mig), CXCL10 (IP- 10) and CXCL11 (I-TAC). Activation of CXCR3 by these endogenous agonists elicits intracellular Ca2+ mobilization via phospholipases C (PLC) and, in addition, activation of both mitogen-activated protein kinase (MAP-kinase) and PI3-kinase [Liu, M; Guo, S; Hibbert, J.M; Jain, V; Sinh, N Wilson, N.O; and Stiles, J.K. 201 1. Cytokine & Growth Factor Reviews, 22: 121-130.]. These intracellular events finally result in stimulation of lymphocyte migration and proliferation. CXCR3 plays a key role in selective recruitment of activated immune cells to the site of inflammation. Once recruited, cytotoxic T cells (CTL), through the release of perforin and granzyme B, induce apoptosis, thereby contributing to local tissue damage and subsequent remodelling. At the site of inflammation the recruited Thl and CTL cells release IFN-gamma that stimulates epithelial cells and macrophages to further release of CXCR3 agonists that leads to a persistent inflammatory activation.
Strong Thl and CTL responses are beneficial during acute infection, but these responses must be counterbalanced to prevent unwanted tissue destruction and chronic immunopathological changes [Groom, J.R. and Luster, A.D. 201 1. Experimental Cell Research 317: 620-631]. In this respect CXCR3 antagonists are suggested to have significant therapeutic relevance.
More recent studies demonstrated that CXCR3 is also expressed on human CD25+ FOXP3+ regulatory CD4+ T cells (Treg) and the level of CXCR3 increases on Treg cells following activation [Vandercappellen, J et al, 201 1. Cytokine & Growth Factor Reviews 22: 1- 18.]. This observation suggests that CXCR3 may participate in mediation of trafficking of Treg cells. Treg cells migrate to the peripheral sites of inflammation, where they exert suppressive activity on CD4+ Thl and CD8+ CTL cells [Hoerning, A et al 2011. Eur J Immunol, online manuscript, accepted: April 26, 201 1. DOI: 10.1002/ej i .201041095] . Thus Treg cells are important for suppressing the immune responses, maintaining immune tolerance and preventing autoimmune responses.
For the time being little is known about the expression pattern of CXCR3 on Treg subsets or the association of CXCR3 with Treg immunoregulatory functions. However, this finding may explain some reported variable functional effects of CXCR3 blockade in different animal models [Hoerning, A et al 201 1. Eur J Immunol, online manuscript, accepted: April 26, 201 1. DOI: 10.1002/ej i.201041095] or the variable effects of CXCR3 blockade in different types of allograft rejection.
As of today, there are three splice variants for CXCR3 described in humans: CXCR3-A,
CXCR3-B [Romagnani, P; Lasagni, L; Annunziato, F; Serio, M. and Romagnani, S. 2004. TRENDS in Immunology, 25: 201-209.] and CXCR3-alt. CXCR3-A is the most abundant variant, it couples to Gi/o type of G-proteins and it mediates chemotaxis and cell proliferation.
The splice variant CXCR3-B is thought to be expressed on endothelial and vascular smooth muscle cells and mediates angiostatic effects [Strieter, R.M; Burdick, M.D; Gomperts, B.N; Belperio, .A; Keane, MP. 201 1. Cytokine & Growth Factor Reviews 16:593-609.]. CXCR3-B can bind not only the three well known CXCR3 agonists, CXCL9 (Mig), CXCL10 (IP-10) and CXCLl l (I-TAC). but also a forth one, CXCL4 (PF-4), which is a selective, CXCR3-B specific chemokine agonist. Activation of CXCR3-B is supposed to mediate the activation of the Gs, the stimulatory type of G-proteins that in turn causes an intracellular cAMP rise, which finally results in angiostatic effects and inhibition of cell proliferation. More recent studies, however, showed that the alternative CXCR3-B splice variant does not exist in mice [Campanella, G.S.V; Colvin, R.A; and Luster, A.D. 2010. PLoS ONE 5(9): el2700. doi: 10.1371/journal.pone.0012700] and, in addition to it, the same authors in their experiments with human endothelial cells also demonstrated that CXCL10 can inhibit endothelial cell proliferation independently of CXCR3 receptors. As of today, there are some controversial observations on the putative roles of the different alternative CXCR3 splice variants and thus further studies are still needed in order to clarify and understand their physiological and pathophysiological roles.
On the other hand, it is widely accepted that T lymphocytes play crucial regulatory function in the immune system [Wijtmans, M; Verzijl, D; Leurs, R; de Esch, I.J.P; and Smit, M.J. 2008. ChemMedChem. 3:861-872.] and [Muller, M; Carter, M.J; Hofert, J; and Campbell, I.L. 2010. Neuropathology and Applied Neurobiology, 36:368-387.]. Their special roles are also indicated by the fact that 15 chemokine receptors out of the 20 known ones, are expressed among the different subpopulations of T lymphocytes [Pease and Williams, Br. J. Pharmacol. 2006. 147, S212]. T cells are implicated in many inflammatory diseases. Clinical evidences showed significant overexpression of CXCR3 receptor and/or its endogenous agonists (CXCL10, CXCL1 1) in multiple autoimmune or inflammatory diseases, such as e.g.
(i) in peripheral airways of COPD patients [Donnelly, L.E. and Barnes , P.J. Trends in Pharmacol Sci 27(10): 564-553.],
(//') in skin biopsies from patients with moderate to severe psoriasis [Chen, S-C; Groot, M.; Kinsley, D; Laverty, M; McClanahan, T; Arreaza, M; Gustafson, E.L; Teunissen, M.B.M; Rie, M.A; Jay, S.F; and Kraan, M. 2010. Arch. Dermatol. Rev. 302: 113-123],
(/'/'/') in lymph nodes and islets of type 1 diabetic patients [Uno, S; Imagawa, A; Saisho, K; Okita, K; Iwahashi, H; Hanafusai, T; and Shimomura, I. 2010. Endocrine Journal. 57(1 1): 991 -996.] (zv) in acute allograft rejection (lung, heart, kidney and skin grafts) [Wenczel, J. Lucas, S; Zahn, S; Mikus, S; Metze, D; Stadter, S, et al, 2008. J. Am. Acad. Dermatol. 58:437-442.]
(v) in colon biopsies of patients with ulcerative colitis [Singh, U.P. Singh, R; Singh, S; Karls, R.K; Quinn, F.D; Taub, D.D; and Lillard Jr J.W. 2008. BMC Immunology 9:25]
and (vi) in thymus from myasthenia gravis patients [Pease, J.E and Horuk, R. 2009. Expert Opin Ther Patents, 19 (2): 199-221].
In animals, CXCR3-KO mice display blocked T cell migration into bronchoalveolar space following noxious stimuli such as cigarette smoke (murine model of COPD). CXCLlO-gene deficient or CXCR3-KO mice showed prolonged allograft survival in murine models of transplant rejection (cardiac and pancreatic island allografts).
Blocking the activation of CXCR3 by antagonists represents a possible approach for the treatment of diseases such as COPD [Hansel, T.T. and Barnes, P.J. 2009. Lancet, 374:744-755], psoriasis [Krueger, J.G. and Bowcock, A. 2005. Ann. Rheum. Dis. 64: Suppl.IL: ii30-ii36.], graft/transplant rejection [Hancock, W.W; Lu, B; Gao, W; Cziszmadia, V; Faia, K; King, J.A; Smileey, S.T; Ling, M; Gearad, N.P; and Gerard, C. 2000. J Exp Med 192: 1515-1519.], ophthalmological diseases [ Sorensen, T.L; Roed, H; Sellebjerg, F. 2004. Br. J. Opthalmol. 88: 1 146-1 148.], celiac disease [Lammers, K.M; Khandelwal, S; Chaudhry, F; Kryszak, D; Puppa, E.L; Casolaro; V; and Fasano, A. 2010. Immunology, 132:432-440.], inflammatory bowel disease (IBD) [Nishimura, M; Kuboi, Y; Muramato, K; Kawano, T; and Imai, T. 2009. Autoimmunity: Ann N.Y. Acad. Sci. 1 173:350-356.] , type 1 diabetes [Shimida, A; Oikawa, Y; Yamada, Y; Okubo, Y; and Narumi, S. 2009. Review of Diabetic Studies, 6(2): 81-84], myasthenia gravis (MG) [Pease, J.E and Horuk, R. 2009. Expert Opin Ther Patents, 19 (2): 199- 221 ], multiple sclerosis (MS) and other neuroinflammatory diseases [Miiller, M; Carter, MJ; Hofert, J; and Campbell, I.L. 2010. Neuropathology and Applied Neurobiology, 36:368-387.], lupus [Lacotte, S; Brun, S; Muller, S; and Dumortier, H. 2009. Autoimmunity: Ann N.Y. Acad. Sci. 1 173:310-317.], rheumatoid arthritis (RA) [Brightling, C; Ammit, A.J; Kaur, D; Black, J.L; Wardlaw, A.J; Hughes, J.M; and Bradding, P. 2005. Am J Respir Crit Care Med. 171 : 1 103- 1 108.], lichen planus [Meller, S; Gillier, M; and Homey, B. 2009. J. Investigative Dermatology. 129: 315-319.].
Targeting CXCR3 appears a more straightforward way to treat the condition as this abrogates the effects of all three endogenous CXCR3 chemokines at the same time.
Assorted patent applications and granted patents disclose inhibitors of chemokines or CXCR3 receptor, such as WO2003087063, WO200604924, WO2009094168 and WO2009105435 but the known compounds are structurally very different from the compounds according to the present invention.
We aimed to prepare new CXCR3 receptor antagonist compounds, which have strong antagonistic effect and are selective to the CXCR3 receptor. We also aimed that the stability, bioavailability, metabolism, therapeutic index, toxicity and solubility of the new compounds allow their development into a drug substance. A further aim was that the compounds, due to their favourable enteric absorption, can be administered orally.
Thus, the inventors of the present invention have identified compounds represented by the following formula 1 possessing inhibitory activity against CXCR3 receptors.
The present invention thus provides a compound of formula 1
1 - wherein
R represents hydrogen or C1-4 alkyl group;
1 represents a group selected from the group consisting
R3 represents hydrogen, halogen, CF3, CN or Ci-4 alkyl; and
R4 represents hydrogen, halogen or C1-4 alkyl-;
a = 0, 1 or 2; b = 0, 1, 2 or 3, c = 1, 2 or 3, and
RA, RB, RC and RD represent independently from each other H or C alkyl;
X represents a C2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a heteroatom selected from O and S, or -CH(CH2)CH-;
Y represents hydrogen, halogen, C alkyl, CM alkoxy or C hydroxyalkyl;
Z represents a C aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, NH and N(CH3) or represents a C2-4 aliphatic hydrocarbon bridge fused with a C3.6 cycloalkyl ring optionally containing one or more double bond or with a phenyl ring or represents a CM aliphatic hydrocarbon bridge substituted with a spiro C3-6 cycloalkyl ring optionally containing one or more double bond;
or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
According to another aspect of the present invention, there is provided a process for the preparation of a compound of formula 1 or a pharmaceutically acceptable salt, stereoisomer or a pharmaceutically acceptable salt of the stereoisomer, comprising the steps of reductive amination of a benzaldehyde of formula 4
-wherein X, Y and Z have the meaning as defined above- with a primary amine of formula 5
R1 NH2
5
-wherein R1 has the meaning as defined above- reacting the obtained secondary amine of formula 2 with a formyl- or oxocycloalkane carboxylic acid ester of formula 3
COOR
(CRaRb)b (CRcRd)
R'
3
-wherein R, Ra, Rb, Rc,Rd, b, and c have the meaning as defined above and R' represents -CHO or =0 - and optionally hydrolyzing the obtained ester of formula 1.
According to another aspect of the present invention there is provided a pharmaceutical composition containing at least one compound of formula 1 or a pharmaceutically acceptable salt, stereoisomer or a pharmaceutically acceptable salt of the stereoisomer and at least one pharmaceutically acceptable excipient.
According to a further aspect the present invention is directed to the compounds of formula 1 or a pharmaceutically acceptable salt, stereoisomer or a pharmaceutically acceptable salt of the stereoisomer for use in the preventive and/or therapeutic treatment of a CXCR3 receptor mediated disease or disorder, especially of a disease or disorder selected from the group consisting of COPD, psoriasis, graft/transplant rejection, ophthalmological disease, celiac disease, inflammatory bowel disease (IBD), type 1 diabetes, myasthenia gravis (MG), multiple sclerosis (MS) and other neuroinfiammatory diseases, lupus, rheumatoid arthritis (RA) or lichen planus. In addition the present invention is directed to a method of treating a CXCR3 receptor mediated disease or disorder, especially of a disease or disorder selected from the group consisting of COPD, psoriasis, graft/transplant rejection, ophthalmological disease, celiac disease, inflammatory bowel disease (IBD), type 1 diabetes, myasthenia gravis (MG), multiple sclerosis (MS) and other neuroinflammatory diseases, lupus, rheumatoid arthritis (RA) or lichen planus comprising administering an effective amount of a compound of formula 1 or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer to a patient in need thereof.
As used above and throughout the description of the invention, the following terms, unless otherwise indicated, are to be understood to have the following meanings:
The Ci-4 alkyl group represents a straight or branched alkyl group having 1 to 4 carbon atoms, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, and the like.
The C alkoxy group represents an above identified alkyl group having 1 to 4 carbon atoms and attached through an oxygen atom, for example, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, and the like.
The Ci-4 hydroxyalkyl group represents an above indentified alkyl group having 1 to 4 carbon atoms and bearing one or more hydroxy group, for example, hydro xymethyl group, 1- hydroxy-ethyl group, 2- hydroxy-ethyl group, 1 -, 2- or 3- hydroxy- n-propyl group, 1 - or 2- hydroxy-isopropyl group, and the like.
The halogen atom represents a fluorine, chlorine, bromine or iodine atom.
The C2 aliphatic hydrocarbon bridge optionally containing a double or a triple bond or a heteroatom selected from O and S means an alkandiyl group having 2 carbon atoms and optionally containing a double or a triple bond or a heteroatom selected from O and S, for example, -CH2-CH2-, -CH=CH-, -C≡C-, -0-CH2-, -S-CH2-, and the like.
The Ci_4 aliphatic hydrocarbon bridge optionally containing one double bond and/or one or more heteroatom selected from O, S, NH and N(CH3) means an alkandiyl group having 1 to 4 carbon atoms and optionally containing one double bond and/or one or more heteroatom selected from O, S, NH and N(CH3), for example -CH2-CH2-, -CH2-0-, -CH2-S-, -CH2-NH-, -CH2- N(CH3)-, -CH2-CH2-CH2-, -CH=CH-N(CH3)-, -N=CH-N(CH3)-, and the like. The C2.4 aliphatic hydrocarbon bridge fused with a C3-6 cycloalkyl ring optionally containing one or more double bond or with a phenyl ring means an alkandiyl group having 2 to 4 carbon atoms and fused with a cycloalkyl ring having 3 to 6 carbon atoms and optionally containing one or more double bond or with a phenyl ring for example cyclopropandiyl ,
The C aliphatic hydrocarbon bridge substituted with a spiro C3-6 cycloalkyl ring optionally containing one or more double bond means an alkandiyl group having 1 to 4 carbon atoms and substituted with a spiro cycloalkyl ring having 3 to 6 carbon atoms and optionally
containing one or more double bond, means for example
— I—
In the formulae the bond crossed by dotted line ' represents the attachment of the substituent with the other parts of the compound.
By salts of the compounds of the formula 1 we mean salts formed with inorganic and organic acids. Preferred salts are those given with pharmaceutically acceptable acids as for instance hydrochloric acid, and the like. The salts formed during purification or isolation are also subject of the invention.
The compounds represented by the aforementioned formula 1 may have one or more asymmetric carbon atoms. Thus, they can exist in the form of optical isomers, enantiomers or diastereoisomers.
The compounds of formula 1 can also exist in the form of cis (Z) or trans (E) stereoisomers. These stereoisomers, enantiomers and diastereoisomers as well as their mixtures, including the racemates, are also subject of the invention.
One of the embodiments of the present invention includes compounds of formula 1 wherein
R represents hydrogen or Cj.4 alky 1;
wherein R2 represents hydrogen or C1-4 alkyl;
R3 represents hydrogen, halogen, CF3, CN or C
R4 represents hydrogen, halogen or Ci-4 alkyl;
= 0 or l ; b = 0, 1 or 2, c = 1, 2 or 3; and
COOR
(CRaRb)b (CR
represents a cycloalkane' carboxylic acid or ester thereof, selected from the group consisting of
- wherein R° and R represent independently from each other H or C1-4 alkyl;
X represents -0-CH2-, -S-CH2-, -CH=CH-, -CH2-CH2-, -C≡C- or cyclopropandiyl;
Y represents hydrogen, halogen; C1-4 alkyl, C1-4 alkoxy or C1-4 hydroxyalkyl;
Z represents a Ci_4 aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, N and N(CH3) or represents a C2- aliphatic hydrocarbon bridge fused with a C3.6 cycloalkyl ring optionally containing one or more double bond or with a phenyl ring or represents a Cj-4 aliphatic hydrocarbon bridge substituted with a spiro C3.6 cycloalkyl ring optionally containing one or more double bond or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
Another embodiment of the present invention includes compounds of formula 1 wherein R represents hydrogen, or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
Another embodiment of the present invention includes compounds of formula 1 wherein 1 represents a group selected from the group consisting of
R3 represents CI, F, CF3, CN, methyl or ethyl; and
R4 represents hydrogen, CI, F or methyl;
or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
Another embodiment of the present invention includes compounds of formula 1 wherein R1 represents a group selected from the group consisting of
wherein R2 represents methyl or ethyl; and
R4 represents hydrogen, CI or F;
or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
Another embodiment of the present invention includes compounds of formula 1 wherein R1 represents a group selected from the group consisting of wherein R2 represents methyl or ethyl; and
R4 represents hydrogen, CI or F;
or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoi somer.
Another embodiment of the present invention includes compounds of formula 1 wherein X represents -0-CH2-, -S-CH2- or -CH2-CH2-, or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
Another embodiment of the present invention includes compounds of formula 1 wherein
Y represents hydrogen, CI, F, methyl, ethyl, methoxy or -CH2-OH; or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
Another embodiment of the present invention includes compounds of formula 1 wherein
Y represents ethyl or methoxy; or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
Another embodiment of the present invention includes compounds of formula 1 wherein Z represents -(CH2)2-, -(CH2)3-, -CH2-0-, -CH2-S-, -CH2-N(CH3)-, -CH=CH-N(CH3)-, -N=CH- N(CH3)-,
cyclopropandiyl, -,
or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
Another embodiment of the present invention includes compounds of formula 1 wherein
Z represents -(CH2)2- or -CH2-N(CH3)-; or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
Another embodiment of the present invention includes compounds of formula 1 wherein
R represents hydrogen, methyl or ethyl; R1 represents a group selected from the
- wherein R represents hydrogen methyl or ethyl;
R3 represents hydrogen, chloro, fluoro, CF3, CN, methyl or ethyl; and
RR44 rreepprreesseennttss hhyyddrrooggeenn,, cchhlloro, fluoro, methyl or ethyl;
a = 0 or 1 ; b = 0, 1 or 2, c = 1, 2 or 3; and
COOR
(CRaR»)b (CRcRd)c
represents a cycloalkane carboxylic acid or ester thereof, selected from the group consisting of
- wherein Rc and R represent independently from each other H or methyl or ethyl;
X represents -0-CH2-, -S-CH2-, -CH=CH-, -CH2-CH2-, -C≡C- or cyclopropandiyl;
Y represents chloro, fluoro, methyl, ethyl, methoxy or -CH2-OH;
Z represents -(CH2)2-, -(CH2)3-, -CH2-0-, -CH2-S-, -CH2-N(CH3)-, -CH=CH-N(CH3 ,
N(CH3)-, CH(CH2)CH-, -, or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
Particularly compounds of the present invention represented by formula 1 include compounds selected from the group consisting of:
1. ira77i-4-[([l -(2,3-Dihydro-l-benzofuran-5-yl)ethyl]{4-[2-(2,5-dioxo-pyrrolidin-l- yl)ethoxy]-3-methoxybenzyl}amino)methyl]-cyclohexanecarboxylic acid
1.1 trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid ethyl ester
2. c5-4-[([l-(2,3-Dihydro-l -benzofuran-5-yl)ethyl]{4-[2-(2,5-dioxo-pyrrolidin-l- yl)ethoxy]-3-methoxybenzyl}amino)methyl]-cyclohexanecarboxylic acid
3. trara-4-[([(i?)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]- cyclohexanecarboxylic acid
4. trara-4-[([(5)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin- 1 -yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]- cyclohexanecarboxylic acid
5. tram-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- l-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]cyclohexanecarboxylic acid
6. trans-4-[([(R)- 1 -(4-Chloro-phenyl)-ethyl]- {4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
7. trara-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
8. cw-4-[([(lS)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]- 3 -methyl-benzyl} -amino)-methyl]-cyclohexanecarboxylic acid
9. trans -[{[(R)- 1 -(4-Chloro-phenyl)-ethyl]- {4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)- ethoxy]-3-methyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
10. tra« -4-[((5-Chloro-indan- 1 -yl)- {4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
1 1. trara-4-[((^-5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[((fS -5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3- methoxy-benzyl } -amino)-methyl]-cyclohexanecarboxylic acid
cw-4-[((5-Chloro-indan- l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[(((S)-4,5-Dichloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]- 3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid hydrochloride trara-4-[([l-(2,3-Dihydro-benzofliran-5-yl)-ethyl]-{4-[2-(2,4-dioxo-thiazolidin-3- yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid irara-4-({ {3-Chloro-4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-benzyl}-[l-(2,3- dihydro-benzofuran-5-yl)-ethyl]-amino}-methyl)-cyclohexanecarboxylic acid trans- -[([ l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- 1 - yl)-ethoxy]-3-methyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid ir «j'-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin- l -yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid tra«j'-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,4-dioxo-oxazolidin-3- yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid traw-4-[((5-Chloro-indan-l-yl)-{3-chloro-4-[2-(3-methyl-2,5-dioxo-imidazolidin- l-yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
ira«5-4-{[{3-Chloro-4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-benzyl}-(5-chloro- indan-l-yl)-amino]-methyl}-cyclohexanecarboxylic acid
tr ra-4-({ {3-Chloro-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l-yl)-ethoxy]- benzyl}-[l-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amino}-methyl)- cyclohexanecarboxylic acid
trara-4-({ {3-Chloro-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l-yl)-ethoxy]- benzyl } -[(S)- 1 -(4-chloro-phenyl)-ethyl] -amino } -methy l)-cyclohexanecarboxylic acid
ira«5-4-[((5-Chloro-indan-l-yl)-{4-[2-(2,4-dioxo-thiazolidin-3-yl)-ethoxy]-3- methoxy-benzyl }-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([l-(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid tr ra-4-[([(S)-l-(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[([( ?)- l -(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid tra ?,s-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-propyl]-{3-methoxy-4-[2-(3-methyl-
2.5- dioxo-imidazolidin- 1 -yl)-ethoxy]-benzyl } -amino)-methyl]- cyclohexanecarboxylic acid
tram-4-[((5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin- l-yl)-ethoxy]-3- methyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[(((S)-5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[(((^)-5-Chloro-indan- l -yl)-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3- methyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
iram-4-({ {3-Chloro-4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-benzyl}-[(5)- l -(4- chloro-phenyl)-ethyl]-amino}-methyl)-cyclohexanecarboxylic acid
tram-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,4-dioxo-thiazolidin-3- yl)-ethoxy]-3-methyl-benzyl}-an ino)-methyl]-cyclohexanecarboxylic acid trara-4-[([(S)- l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,4-dioxo-thiazolidin-3-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tra«5-4-[([l-(2,3-Dihydro-benzofliran-5-yl)-ethyl]-{4-[(E)-3-(2,5-dioxo- pyrrolidin- 1 -yl)-propenyl]-3 -methoxy-benzyl } -amino)-methy 1] - cyclohexanecarboxylic acid
iraf75-4-[([(S)- l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,4-dioxo-oxazolidin-3-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tram-4-[([(S)- l-(4-Chloro-phenyl)-ethyl]-{3-methoxy-4-[2-(3-methyl-2,6-dioxo-
3.6- dihydro-2H-pyrirnidin- 1 -yl)-ethoxy] -benzyl } -amino)-methyl] - cyclohexanecarboxylic acid
trora-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,6-dioxo-piperidin-l - yl)-ethoxy]-3 -methoxy-benzyl } -amino)-methyl] -cyclohexanecarboxylic acid trara-4-[([(5)-l -(4-Chloro-phenyl)-ethyl]-{3-methyl-4-[2-(3-methyl-2,5-dioxo- imidazolidin- 1 -yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[3-(2,5-dioxo-pyrrolidin-l- yl)-propyl]-3 -methoxy-benzyl } -amino)-methyl] -cyclohexanecarboxyl ic acid 3-[([l-(2,3-Dihydro-benzofliran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trarcs-4-[((5-Chloro-6-methyl-indan- 1 -yl)- {4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)- ethoxy] -3 -methoxy-benzyl }-amino)-methyl]-cyclohexanecarboxylic acid tra«5-4-[((5-Chloro-4-methyl-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[((5-Chloro-indan-l-yl)-{4-[3-(2,5-dioxo-pyrrolidin-l -yl)-propyl]-3- methoxy-benzyl } -amino)-methyl] -cyclohexanecarboxylic acid
trara-4-[(((/?)-5-Chloro-indan-l-yl)-{4-[3-(2,5-dioxo-pyrrolidin-l-yl)-propyl]-3- methoxy-benzyl } -amino)-methyl] -cyclohexanecarboxylic acid
trao5-4-[(((5 -5-Chloro-indan-l-yl)-{4-[3-(2,5-dioxo-pyrrolidin-l-yl)-propyl]-3- methoxy-benzyl}-amino)-methyl] -cyclohexanecarboxylic acid
tram-4-({{3-Chloro-4-[3-(2,5-dioxo-pyrrolidin-l-yl)-propyl]-benzyl}-[l-(2,3- dihydro-benzofuran-5-yl)-ethy 1] -amino } -methyl)-cyclohexanecarboxylic acid trans A- [((5-Chloro-indan- 1 -yl)- { 3-methoxy-4-[2-(3 -methyl-2,6-dioxo-3 ,6- dihydro-2H-pyrimidin- 1 -yl)-ethoxy] -benzyl }-amino)-methyl] - cyclohexanecarboxylic acid
trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- 1 - ylmethy l)-cyclopropy 1] -3 -methoxy-benzyl } -amino)-methyl] - cyclohexanecarboxylic acid
trara-4-[((5-Chloro-indan-l-yl)-{3-methoxy-4-[3-(3-methyl-2,5-dioxo- imidazolidin- 1 -yl)-propyl]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{3-methoxy-4-[3-(3-methyl-2,5-dioxo- imidazolidin- 1 -yl)-propyl] -benzyl } -amino)-methyl] -cyclohexanecarboxylic acid irara-4-[((5-Chloro-indan-l-yl)-{3-methoxy-4-[2-(3-methyl-2,5-dioxo- imidazolidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[([(,S)-l-(4-Chloro-phenyl)-ethyl]-{3-methoxy-4-[2-(3-methyl-2,5-dioxo- imidazolidin- 1 -yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trans-4-[([(S)- 1 -(4-Chloro-phenyl)-ethyl]-{4-[3-(2,5-dioxo-pyrrolidin- 1 -yl)- propyl]-3-methyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
/rara-4-[([(S)-l-(4-Chloro-phenyl)-ethyl]-{4-[3-(2,5-dioxo-pyrrolidin-l-yl)-prop- 1 -ynyl]-3 -methoxy-benzyl } -amino)-methyl] -cyclohexanecarboxylic acid trara-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[3-(2,5-dioxo-pyrrolidin-l -yl)- propyl]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[((5-Chloro-indan-l-yl)-{3-methyl-4-[2-(3-methyl-2,5-dioxo- imidazolidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid irara-4-[([(5)-l -(4-Chloro-phenyl)-ethyl]-{3-methyl-4-[2-(3-methyl-2,6-dioxo- 3 ,6-dihydro-2H-pyrimidi n- 1 -yl)-ethoxy] -benzyl } -amino)-methyl]- cyclohexanecarboxylic acid
trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methoxy-4-[2-(3-methyl- 2,6-dioxo-3,6-dihydro-2H-pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]- cyclohexanecarboxylic acid
traw-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methyl-4-[2-(3-methyl-2,6- dioxo-3,6-dihydro-2H-pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]- cyclohexanecarboxylic acid
iran5-4-[([l-(4-Cyano-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trans-A- [([1 -(4-Cyano-phenyl)-ethyl]- { 3 -methoxy-4-[2-(3 -methy l-2,6-dioxo-3 ,6- dihydro-2H-pyrimidin- 1 -yl)-ethoxy] -benzyl } -amino)-methyl] - cyclohexanecarboxylic acid
trara-4-[([l -(4-Chloro-phenyl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]- 3 -methoxy-benzyl } -amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([l-(4-Chloro-phenyl)-propyl]-{3-methyl-4-[2-(3-methyl-2,6-dioxo-3,6- dihydro-2H-pyrimidin-l -yl)-ethoxy]-benzyl}-amino)-methyl]- cyclohexanecarboxylic acid
trara-4-[([l-(4-Chloro-phenyl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]- 3 -methyl-benzyl } -amino)-methyl]-cyclohexanecarboxylic acid
trans-A- [([ 1 -(2,3-Dihydro-benzofuran-5 -yl)-propyl]- { 4- [3 -(2,5 -dioxo-pyrrolidin- l-yl)-propyl]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid ir ra-4-[([l-(4-Chloro-phenyl)-propyl]-{3-methoxy-4-[2-(3-methyl-2,5-dioxo- imidazolidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid tra«1y-4-[([l-(4-Chloro-phenyl)-propyl]-{3-methoxy-4-[2-(3-methyl-2,6-dioxo- 3 ,6-dihydro-2H-pyrimidin- 1 -yl)-ethoxy] -benzyl } -amino)-methyl] - cyclohexanecarboxylic acid
tra«i-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-propyl]-{4-[2-(2,5-dioxo-pynOlidin- l-yl)-ethoxy]-3-methyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[([l-(4-Chloro-phenyl)-propyl]-{3-methyl-4-[2-(3-methyl-2,5-dioxo- imidazolidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid tra«5-4-[(((S -5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3- ethyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tra«5-4-[(((5)-5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- fluoro-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tr ra-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-fluoro-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tr ra-4-[(((S)-5,6-Dichloro-indan- 1 -yl)-{4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy]- 3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tra»5-4-[([(S -l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-ethyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l- yl)-ethoxy]-3-ethyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[([l-(3,4-Dichloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[([l-(3,4-Dichloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[([(S)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy] -benzyl } -amino)-methyl]-cyclohexanecarboxylic acid
tram-4-[([l-(3,4-Dichloro-phenyl)-ethyl]-{3-methyl-4-[2-(3-methyl-2,5-dioxo- imidazolidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trans-4-({ {4-[2-(2,5-Dioxo-pyrrolidin- 1 -yl)-ethoxy]-3-methoxy-benzyl}-[ 1 -(4- ethyl-phenyl)-ethyl]-amino}-methyl)-cyclohexanecarboxylic acid 82. trara-4-[([l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
83. tra«^-4-{[{4-[2-(2,5-Dioxo-pyrrolidin-l-yl)-ethoxy]-3-methyl-benzyl}-(l-p-tolyl- ethyl)-amino] -methyl} -eye lohexanecarboxylic acid
84. tra«i,-4-{[{4-[2-(2,5-Dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-(l-p- tolyl-ethyl)-amino]-methyl}-cyclohexanecarboxylic acid
85. trora-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- 1-yl)- ethoxy]-3-hydroxymethyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
86. tram-4-[(((5)-4,5-Dichloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]- 3-ethyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
87. trara-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidiri-l -yl)- ethylsulfanyl]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
88. tra«5-4-[(((S)-5-Chloro-indan- 1 -yl)- {4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)- ethylsulfanyl]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid 89. trara-4-[([l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)- ethoxy]-3-ethyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
90. trara-4-[([(^)-l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l- yl)-ethoxy]-3-ethyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
91. ?ra«.s-4-[([(S)-l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l- yl)-ethoxy] -3 -ethyl-benzyl } -amino)-methyl] -cyclohexanecarboxylic acid
92. tm«i-4-[([l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- l-yl)- ethoxy]-3-fluoro-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
93. trara-4-[((4-Chloro-5-fluoro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
94. tra«5-4-[((6-Chloro-5-fluoro-indan- 1 -yl)- {4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
95. trara-4-[((6-Chloro-5-fluoro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-ethyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
96. trara-4-[((4-Chloro-5-fluoro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)- ethoxy]-3-ethyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid 97. trara-4-[((6-Chloro-5-fluoro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy] -3 -fluoro-benzyl } -amino)-methyl] -cyclohexanecarboxylic acid
98. trara-4-[((5-Chloro-6-fluoro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
99. (ii?,5i?)-3-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid
100. (75,,5¾-3-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l- yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid
101. (/i?,J5)-3-[([(5 -l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l- yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid
102. (i5,,5^)-3-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l- yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid
103. (7i?,J5)-3-[([(^)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin- 1 -yl)-ethoxy] -3 -methoxy-benzyl } -amino)-methyl]- cyclopentanecarboxylic acid
104. (i/?,5i?)-3-[([(/?)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin- 1 -yl)-ethoxy]-3-methoxy-benzyl }-amino)-methyl]- cyclopentanecarboxylic acid
105. (ii?,5/?)-3-[([(5)-l-(2,3-Dihydro-benzofliran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]- cyclopentanecarboxylic acid
106. (i5',5i?)-3-[([(5)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin- 1 -yl)-ethoxy] -3 -methoxy-benzyl } -amino)-methyl] - cyclopentanecarboxylic acid
107. (/ ?,55)-3-[([(5)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]- cyclopentanecarboxylic acid
108. (75',i/?)-3-[([(/?)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]- cyclopentanecarboxylic acid . (75',J5)-3-[([( ?)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]- cyclopentanecarboxylic acid
. (75',i5)-3-[([(5)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]- cyclopentanecarboxylic acid
. (ii?,2i?)-2-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin- 1 -yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]- cyclopropanecarboxylic acid ethyl ester
. (7i?,2i?)-2-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin- 1 -yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]- cyclopropanecarboxylic acid
. (7S')2/?)-2-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin- 1 -yl)-ethoxy]-3-methoxy-benzyl }-amino)-methyl]- cyclopropanecarboxylic acid ethyl ester
. (i5,2/?)-2-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]- cyclopropanecarboxylic acid
. (ii?,5/i)-3-[([l -(4-Chloro-phenyl)-propyl]-{3-methyl-4-[2-(3-methyl-2,5- dioxo-imidazolidin- 1 -yl)-ethoxy] -benzyl } -amino)-methyl] -2,2-dimethyl- cyclopropanecarboxylic acid
. (75,,55)-3-[([l-(4-Chloro-phenyl)-propyl]-{3-methoxy-4-[2-(3-methyl-2,5- dioxo-imidazolidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]-2,2-dimethyl- cyclopropanecarboxylic acid
. (75,,55)-3-[([l-(4-Chloro-phenyl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin-l- yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-2,2-dimethyl- cyclopropanecarboxylic acid
. (77?,57?)-3-[([l-(4-Chloro-phenyl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin-l- yl)-ethoxy]-3-methyl-benzyl}-amino)-methyl]-2,2-dimethyl- cyclopropanecarboxylic acid . l-[((5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl } -amino)-methyl] -cyclopropanecarboxylic acid
. trara-3-([l-(2,3-Dihydro-benzof iran-5-yl)-ethyl]-{3-methoxy-4-[2-(3- methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-l-yl)-ethoxy]-benzyl}-amino)- cyclobutanecarboxylic acid
. m-3-([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methoxy-4-[2-(3- methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-l-yl)-ethoxy]-benzyl}-amino)- cyclobutanecarboxylic acid
. ci5-3-([(/?)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methoxy-4-[2-(3- methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-l -yl)-ethoxy]-benzyI}-amino)- cyclobutanecarboxylic acid
. cis-3-([(S)- 1 -(2,3 -Dihydro-benzofuran-5 -yl)-ethy 1] - { 3-methoxy-4-[2-(3 - methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-l -yl)-ethoxy]-benzyl}-amino)- cyclobutanecarboxylic acid
. tram-3-([l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy]-3-methyl-benzyl} -amino)-cyclobutanecarboxylic acid
. cw-3-([l -(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l- yl)-ethoxy]-3-methyl-benzyl}-amino)-cyclobutanecarboxylic acid
. 3-([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l- yl)-ethoxy]-3-methoxy-benzyl}-amino)-cyclobutanecarboxylic acid
. 3-((5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl}-amino)-cyclobutanecarboxylic acid
. tram-3-([(i?)-l-(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin-l-yl)-ethoxy]-3-methyl-benzyl}-amino)-cyclobutanecarboxylic acid. m-3-([(i?)-l-(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin-l-yl)-ethoxy]-3-methyl-benzyl}-amino)-cyclobutanecarboxylic acid. tra«5-3-([(5)-l-(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin-l-yl)-ethoxy]-3-methyl-benzyl}-amino)-cyclobutanecarboxylic acid. cw-3-([(5)-l-(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin- 1 -yl)-ethoxy]-3-methyl-benzyl}-amino)-cyclobutanecarboxylic acid . cw-3-([(i?)-l -(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methyl-benzyl}-amino)-cyclobutanecarboxylic acid
. cw-3-((5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3- methyl-benzyl}-amino)-cyclobutanecarboxylic acid
. CIJ-3-([1 -(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methyl-4-[2-(3-methyl 2,6-dioxo-3,6-dihydro-2H-pyrimidin- 1 -yl)-ethoxy] -benzyl } -amino)- cyclobutanecarboxylic acid
. cw-3-([l -(2,3-Dihydro-benzofuran-5-yl)-propyl]-{4-[2-(2,5-dioxo- pytTolidin-l-yl)-ethoxy]-3-methyl-benzyl}-amino)-cyclobutanecarboxylic acid. cis-3-([(R)-\ -(4-Chloro-phenyl)-ethyl]-{3-methyl-4-[2-(3-methyl-2,6- dioxo-3,6-dihydro-2H-pyrimidin-l -yl)-ethoxy]-benzyl}-amino)- cyclobutanecarboxylic acid
. c/.s-3-([l -(3,4-Dichloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pytTolidin-l-yl)- ethoxy]-3-methoxy-benzyl}-amino)-cyclobutanecarboxylic acid
. cw-3-([ I -(3,4-Dichloro-phenyl)-ethyl]- {4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)- ethoxy] -3 -methyl-benzyl} -amino)-cyclobutanecarboxylic acid
. c/.y-3-([l -(3,4-Dichloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-ethyl-benzyl}-amino)-cyclobutanecarboxylic acid
. ci'5-3-([l -(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l yl)-ethoxy]-3-ethyl-benzyl}-amino)-cyclobutanecarboxylic acid
. cw-3-([l -(3,4-Dichloro-phenyl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin- l-yl) ethoxy] -3 -methoxy-benzyl } -amino)-cyc lobutanecarboxyl ic acid
. cw-3-([l -(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l yl)-ethoxy]-3-methoxy-benzyl}-amino)-cyclobutanecarboxylic acid
. cw-3-([(i?)-l-(4-Chloro-phenyl)-ethyl]-{4-[3-(2,5-dioxo-pyrrolidin-l-yl)- propyl] -3 -methyl -benzyl }-amino)-cyclobutanecarboxylic acid
. tra«5-4-{[{4-[2-(2,5-Dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}- (1 -indan-5-yl-ethyl)-amino]-methyl}-cyclohexanecarboxylic acid
. trans-A-[({ 1 -Indan-5 -yl-ethyl)- { 3 -methoxy-4-[2-(3 -methyl-2,5-dioxo- imidazolidin- l -yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid . -4-[(((S)-5-Chloro-indan-l-yl)-{4-[2-(2,4-dioxo-3-aza-bicyclo[3.1.0]hex- 3-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid. 4-[(((S)-5-Chloro-indan-l-yl)-{4-[2-(7,9-dioxo-8-aza-spiro[4.5]dec-8-yl ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
. tra«5-4-[(((S)-5-Chloro-4-fluoro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin- l-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid. tra«5'-4-[(((S)-5-Chloro-4-fluoro-indan-l -yl)-{4-[2-(2,5-dioxo-pyiTolidin-
1 - yl)-ethoxy]-3-ethyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid. cw-3-([(R)-l -(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin- 1 -yl)-ethoxy]-3-methoxy-benzyl}-amino)-cyclobutanecarboxylic acid. cw-3-([(R)- 1 -(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin-l-yl)-ethoxy]-3-ethyl-benzyl}-amino)-cyclobutanecarboxylic acid. c5-3-([(R)-l-(3,4-Dichloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l - yl)-ethoxy]-3-methoxy-benzyI}-amino)-cyclobutanecarboxylic acid
. cw-3-([(R)-l-(4-Chloro-phenyl)-ethyl]-{3-methyl-4-[2-(3-methyl-2,5- dioxo-imidazolidin- 1 -yl)-ethoxy]-benzyl} -amino)-cyclobutanecarboxylic acid. trans- -({ {4-[2-(2,5-Dioxo-pyrrolidin- 1 -yl)-ethoxy]-3-methoxy-benzyl }- [l-(4-trifluoromethyl-phenyl)-ethyl]-amino}-methyl)-cyclohexanecarboxylic acid. ira«s-4-[(((S)-5-Chloro-indan-l-yl)-{4-[2-((3aS,7aR)-l,3-dioxo- l,3,3a,4,7,7a-hexahydro-isoindol-2-yl)-ethoxy]-3-methoxy-benzyl}-amino)- methyl]-cyclohexanecarboxylic acid; hydrochloride
. traw-4-[(((S)-5-Chloro-indan- 1 -yl)-{4-[2-( 1 ,3-dioxo- 1 ,3-dihydro-isoindol-
2- yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid; hydrochloride
. traw-4-[(((S)-5-Chloro-4-fluoro-indan- 1 -yl)-{3-methyl-4-[2-(3-methyl- 2,5-dioxo-imidazolidin-l-yl)-ethoxy]-benzy]}-amino)-methyl]- cyclohexanecarboxylic acid
. 3-[(((S)-5-Chloro-indan- 1 -yl)-{4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy]-3- methoxy-benzyl }-amino)-methyl]-cyclobutanecarboxylic acid
. cw-3-(((R)- l-Indan-5-yl-ethyl)-{3-methoxy-4-[2-(3-methyl-2,6-dioxo-3,6- dihydro-2H-pyrimidin- 1 -yl)-ethoxy]-benzyl}-amino)-cyclobutanecarboxylic acid 160. trara-3-(((R)-l-Indan-5-yl-ethyl)-{3-methoxy-4-[2-(3-methyl-2,6-dioxo- 3 ,6-dihydro-2H-pyrimidin- 1 -yl)-ethoxy] -benzyl } -amino)-cyclobutanecarboxylic acid
or a pharmaceutically acceptable salt thereof or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
A particular group of the compounds of the present invention represented by formula 1 include compounds selected from the group consisting of:
tra«5-4-[([l -(2,3-Dihydro- l -benzofuran-5-yl)ethyl] {4-[2-(2,5-dioxo-pyrrolidin-l-yl)ethoxy]-3- methoxybenzyl}amino)methyl]-cyclohexanecarboxylic acid
trara-4-[([(S l-(2,3-Dihydro-ben^
3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
traw-4-[([(5)- l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- l-yl)-ethoxy]-3-methoxy- benzyl}-amino)-methyl]cyclohexanecarboxylic acid
trans-4-[([(R)- 1 -(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy]-3-methoxy- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([(lS)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methyl- benzyl } -amino)-methyl]-cyclohexanecarboxylic acid
trans-4-[([(R)- 1 -(4-Chloro-phenyl)-ethy 1]- {4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy]-3-methyl- benzyl }-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[((5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}- amino)-methyl]-cyclohexanecarboxylic acid
tr ra-4-[((f5^-5-Chloro-indan- 1 -yl)-{4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy]-3-methoxy- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[(((5 -4,5-Dichloro-indan- 1 -yl)-{4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy]-3-methoxy- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid hydrochloride
irans-4-[([ 1 -(2,3-Dihydro-benzofuran- methoxy-benzyl } -am i no)-methyl] -cyclohexanecarboxy 1 ic ac id
trara-4-({ {3-Chloro-4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-benzyl}-[l -(2,3-dihydro- benzofuran-5-yl)-ethyl]-amino}-methyl)-cyclohexanecarboxylic acid irara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methyl-benzyl } -amino)-methyl] -cyclohexanecarboxyl ic acid
tm«5-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin- l-yl)-ethoxy]-3- methoxy-benzyl } -amino)-methyl]-cyclohexanecarboxylic acid
tmm-4-[([l-(2,3-Dihydro-benzofliran-5-yl)-ethyl]-{4-[2-(2,4-dioxo-oxazolidin-3-yl)-ethoxy]-3- methoxy-benzy 1 } -amino)-methyl] -cyclohexanecarboxylic acid
trara-4-[((5-Chloro-indan-l-yl)-{4-[2-(2,4-dioxo-thiazolidin-3-yl)-ethoxy]-3-methoxy-benzyl}- amino)-methyl]-cyclohexanecarboxylic acid
tra«i-4-[([l -(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- l-yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl] -cyclohexanecarboxylic acid
trara-4-[([(S)-l-(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl }-amino)-methyl]-cyclohexanecarboxylic acid
traw-4-[(((iS)-5-Chloro-indan-l -yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methyl-benzyl}- amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,4-dioxo-thiazolidin-3-yl)-ethoxy]-3- methyl-benzyl} -amino)-methyl] -cyclohexanecarboxylic acid
trara-4-[([(5)- l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,4-dioxo-thiazolidin-3-yl)-ethoxy]-3-methoxy- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tra«5-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,4-dioxo-oxazolidin-3-yl)-ethoxy]-3-methoxy- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([(5)- l-(4-Chloro-phenyl)-ethyl]-{3-methoxy-4-[2-(3-methyl-2,6-dioxo-3,6-dihydro-2H- pyrimidin-l -yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tra« -4-[([l-(4-Chloro-phenyl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3-methoxy- benzyl }-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([l-(4-Chloro-phenyl)-propyl]-{3-methoxy-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l - yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin- l-yl)-ethoxy]-3- methyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- l -yl)-ethoxy]-3-ethyl- benzyl }-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- ethyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tra«5-4-[([l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl } -amino)-methyl] -cyclohexanecarboxylic acid
trara-4-[([(5 -l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethylsulfanyl^ methoxy-benzyl }-amino)-methyl]-cyclohexanecarboxylic acid
tram-4-[(((S)-5-Chloro-indan- 1 -yl)-{4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethylsulfanyl]-3-methoxy- benzyl}-amino)-methyl] -cyclohexanecarboxylic acid
tra«5-4-[([l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-ethyl- benzyl } -amino)-methy 1] -cyclohexanecarboxyl ic acid
tram-4-[([(1¾-l -(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3- ethyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
(7/?,5^)-3-[([( ?)-l-(2,3-Dihydro-benzofliran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- l-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid
(7i?,i^)-3-[([(5)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid
(/5',55)-3-[([(i?)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid
(IS, 3S)-3 - [([ 1 -(4-Chloro-phenyl)-propyl] - {4- [2-(2,5-dioxo-pyrrol idin- 1 -yl)-ethoxy] -3-methoxy- benzyl}-amino)-methyl]-2,2-dimethyl-cyclopropanecarboxylic acid
cw-3-([(^)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methoxy-4-[2-(3-methyl-2,6-dioxo-3,6- dihydro-2H-pyrimidin- 1 -yl)-ethoxy] -benzyl } -amino)-cyclobutanecarboxylic acid
3-([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl } -amino)-cyclobutanecarboxylic acid
tro«i-4-[(((S)-5-Chloro-4-fluoro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
or a pharmaceutically acceptable salt thereof or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
A further embodiment of the invention includes compounds of formula 4,
4
- wherein
X represents a C2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a heteroatom selected from O and S, or -CH(CH2)CH-;
Y represents hydrogen, halogen, C alkyl, C1-4 alkoxy or Ci- hydroxyalkyl;
Z represents a C|.4 aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, N and N(CH3) or represents a C2-4 aliphatic hydrocarbon bridge fused with a C3.6 cycloalkyl ring optionally containing one or more double bond or with a phenyl ring or represents a C1-4 aliphatic hydrocarbon bridge substituted with a spiro C3- cycloalkyl ring optionally containing one or more double bond.
Particularly compounds represented by formula 4 include compounds selected from the group consisting of
4- [2-(2,5-Dioxo-pyrrolidin- 1 -yl)-ethoxy] -3 -methoxy-benzaldehyde
4-[2-(2,5-Dioxo-pyrrolidin- 1 -yl)-ethoxy]-3-methyl-benzaldehyde
4-[2-(2,5-Dioxo-pyrrolidin- 1 -yl)-ethoxy]-3-ethyl-benzaldehyde
3- Chloro-4-[2-(2,5-Dioxo-pyrrolidin-l-yl)-ethoxy]-benzaldehyde
4- [2-(2,5-Dioxo-pyrrolidin-l-yl)-ethoxy]-3-fluoro-benzaldehyde
4-[2-(2,5-Dioxo-pyrrolidin-l-yl)-ethoxy]-3-hydroxymethyl-benzaldehyde
4-[2-(2,5-Dioxo-pyrrolidin-l-yl)-ethoxy]-benzaldehyde
3-Methoxy-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l-yl)-ethoxy]-benzaldehyde
3-Methyl-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l-yl)-ethoxy]-benzaldehyde
3- Chloro-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l-yl)-ethoxy]-benzaldehyde
4- [2-(2,4-Dioxo-thiazolidin-3 -yl)-ethoxy] -3 -methoxy-benzaldehyde
4-[2-(2,4-Dioxo-thiazolidin-3-yl)-ethoxy]-3-methyl-benzaldehyde
4-[2-(2,4-Dioxo-oxazolidin-3-yl)-ethoxy]-3-methoxy-benzaldehyde
3-Methoxy-4-[2-(3-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-l -yl)-ethoxy]-benzaldehyde
3- Methyl-4-[2-(3-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-l-yl)-ethoxy]-benzaldehyde
4- [2-(2,6-Dioxo-piperidin- 1 -yl)-ethoxy] -3 -methoxy-benzaldehyde 4-[2-(2,5-Dioxo-pyrrolidin-l-yl)-ethylsulfanyl]-3-methoxy-benzaldehyde 4-[(E)-3-(2,5-Dioxo-pyrrolidin-l-yl)-propenyl]-3-methoxy-benzaldehyde
4-[3-(2,5-Dioxo-pyrrolidin- 1 -yl)-prop- 1 -ynyl]-3-methoxy-benzaldehyde
4-[3-(2,5-Dioxo-pyrrolidin- 1 -yl)-prop- 1 -ynyl]-3-methyl-benzaldehyde
3-Methyl-4-[3-(3-methyl-2,5-dioxo-imidazolidin- l-yl)-prop-l -ynyl]-benzaldehyde
3- Methoxy-4-[3-(3-methyl-2,5-dioxo-imidazolidin-l -yl)-prop-l-ynyl]-benzaldehyde
4- [3-(2,5-Dioxo-pyrrolidin-l-yl)-propyl]-3-methoxy-benzaldehyde
4-[3-(2,5-Dioxo-pyrrolidin-l -yl)-propyl]-3-methyl-benzaldehyde
3-Chloro-4-[3-(2,5-dioxo-pyrrolidin- l-yl)-propyl]-benzaldehyde
3- Methoxy-4- [3 -(3 -methyl-2,5 -dioxo-imidazolidin- 1 -yl)-propyl]-benzaldehyde
4- [2-(2,5-Dioxo-pyrrolidin-l -ylmethyl)-cyclopropyl]-3-methoxy-benzaldehyde 4-[2-(2,4-Dioxo-3-aza-bicyclo[3.1.0]hex-3-yl)-ethoxy]-3-methoxy-benzaldehyde 4-[2-((3aS,7aR)-l,3-Dioxo- l,3,3a,4,7,7a-hexahydro-isoindol-2-yl)-ethoxy]-3-methoxy- benzaldehyde
4-[2-(l ,3-Dioxo-l,3-dihydro-isoindol-2-yl)-ethoxy]-3-methoxy-benzaldehyde
4-[2-(7,9-Dioxo-8-aza-spiro[4.5]dec-8-yl)-ethoxy]-3-methoxy-benzaldehyde.
A further embodiment of the invention includes compounds of formula 2
2
- wherein
- wherein R2 represents hydrogen or C1-4 alkyl group;
R3 represents hydrogen, halogen, CF3, CN or Q.4 alkyl; and R4 represents hydrogen, halogen or C] -4 alkyl; X represents a C2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a heteroatom selected from O and S, or -CH(CH2)CH-;
Y represents hydrogen, halogen, Ci-4 alkyl, C1-4 alkoxy or C1-4 hydroxyalkyl;
Z represents a Ci-4 aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, N and N(CH3) or represents a C2-4 aliphatic hydrocarbon bridge fused with a C3.6 cycloalkyl ring optionally containing one or more double bond or with a phenyl ring or represents a Ci-4 aliphatic hydrocarbon bridge substituted with a spiro C3-6 cycloalkyl ring optionally containing one or more double bond;
or a salt thereof.
Particularly compounds represented by formula 2 include compounds selected from the group consisting of
1. l-[2-(4-{[l-(2,3-Dihydro-benzofuran-5-yl)-ethylamino]-methyl}-2-methoxy-phenoxy)- ethyl]-pyrrolidine-2,5-dione naphthalene- 1 ,5-disulfonic acid salt
2. l -[2-(4-{[(S)-l -(4-Chloro-phenyl)-ethylamino]-methyl}-2-methoxy-phenoxy)-ethyl]- pyrrolidine-2,5-dione
3. 1 -[2-(4-{[(R)-l -(4-Chloro-phenyl)-ethylamino]-methyl}-2-methoxy-phenoxy)-ethyl]- pyrrolidine-2,5-dione
4. l-[2-(4-{[(S)-l-(4-Chloro-phenyl)-ethylamino]-methyl}-2-methyl-phenoxy)-ethyl]- pyrrolidine-2,5-dione
5. l-[2-(4-{[(R)-l-(4-Chloro-phenyl)-ethylamino]-methyl}-2-methyl-phenoxy)-ethyl]- pyrrolidine-2,5-dione
6. l-(2-{4-[(5-Chloro-indan-l-ylamino)-methyl]-2-methoxy-phenoxy}-ethyl)-pyrrolidine- 2,5-dione
7. l-(2-{4-[((S)-5-Chloro-indan-l-ylamino)-methyl]-2-methoxy-phenoxy}-ethyl)- pyrrolidine-2,5-dione
8. 1 -(2- {4- [((S)-4,5 -Dichloro-indan- 1 -ylamino)-methyl]-2-methoxy-phenoxy } -ethyl)- pyrrolidine-2,5-dione
9. l-(2-{4-[((S)-5-Chloro-4-fluoro-indan-l -ylamino)-methyl]-2-methoxy-phenoxy}-ethyl)- pyrrolidine-2,5-dione
10. 3- [2-(4- { [ 1 -(2,3 -Dihydro-benzofuran-5 -yl)-ethylamino] -methyl} -2 -methoxy-phenoxy)- ethyl]-thiazolidine-2,4-dione 1 1. l-[2-(2-Chloro-4-{[l-(2,3-dihydro-benzofuran-5-yl)-ethylamino]-methyl}-phenoxy)- ethyl] -pyrro li dine-2 ,5 -dione
12. 1 -[2-(4-{ [ 1 -(2,3-Dihydro-benzofuran-5-yl)-ethylamino]-methyl}-2-methyl-phenoxy)- ethyl] -pyrrolidine-2,5 -dione
13. 1 -[2-(4-{ [1 -(2,3-Dihydro-benzofuran-5-yl)-propylamino]-methyl} -2-methoxy-phenoxy)- ethyl]-pyrrolidine-2,5-dione
14. 3 - [2-(4- { [ 1 -(2,3 -Dihydro-benzofuran-5 -yl)-ethylamino]-methyl } -2-methoxy-phenoxy)- ethyl]-oxazolidine-2,4-dione
15. 3-(2-{2-Chloro-4-[(5-chloro-indan-l-ylamino)-methyl]-phenoxy}-ethyl)-l-methyl- imidazolidine-2,4-dione
16. l-(2-{2-Chloro-4-[(5-chloro-indan-l-ylamino)-methyl]-phenoxy}-ethyl)-pyrrolidine-2,5- dione
17. 3-[2-(2-Chloro-4-{[l-(2,3-dihydro-benzofuran-5-yl)-ethylamino]-methyl}-phenoxy)- ethyl]- 1 -methyl-imidazolidine-2,4-dione
18. 3-[2-(2-Chloro-4-{ [(S)- 1 -(4-chloro-phenyl)-ethylamino]-methyl}-phenoxy)-ethyl]- 1 - methyl-imidazolidine-2,4-dione
19. 3-(2-{4-[(5-Chloro-indan- l-ylamino)-methyl]-2-methoxy-phenoxy}-ethyl)-thiazolidine- 2,4-dione
20. 1 -[2-(4-{ [ l-(4-Chloro-3-methyl-phenyl)-ethylamino]-methyl} -2-methoxy-phenoxy)- ethyl]-pyrrolidine-2,5-dione
21. l-[2-(4-{[(S)-l-(4-Chloro-3-methyl-phenyl)-ethylamino]-methyl}-2-methoxy-phenoxy)- ethyl] -pyrrolidine-2,5 -dione
22. l -[2-(4-{[(R)-l-(4-Chloro-3-methyl-phenyl)-ethylamino]-methyl}-2-methoxy-phenoxy)- ethyl] -pyrrolidine-2,5 -dione
23. 3 -[2-(4- { [ 1 -(2,3 -Dihydro-benzofuran-5 -yl)-propylamino] -methyl } -2-methoxy-phenoxy)- ethyl]-l-methyl-imidazolidine-2,4-dione
24. l-(2-{4-[(5-Chloro-indan- 1 -ylamino)-methyl]-2-methyl-phenoxy}-ethyl)-pyrrolidine-2,5- dione
25. l-(2-{4-[((S)-5-Chloro-indan-l-ylamino)-methyl]-2-methyl-phenoxy}-ethyl)-pyrrolidine- 2,5-dionel-(2-{4-[((R)-5-Chloro-indan-l-ylamino)-methyl]-2-methyl-phenoxy}-ethyl)- pyrrolidine-2,5 -dione 26. 1- [2-(2-Chloro-4- { [(S)- 1 -(4-chloro-phenyl)-ethylamino] -methyl } -phenoxy)-ethyl]- pyrrolidine-2,5-dione
27. 3-[2-(4-{[l -(2,3-Dihydro-benzofuran-5-yl)-ethylamino]-methyl}-2-methyl-phenoxy)- ethyl]-thiazolidine-2,4-dione
28. 3 -[2-(4- { [(S)- 1 -(4-Chloro-pheny l)-ethylamino] -methyl } -2-methoxy-phenoxy)-ethy 1] - thiazolidine-2,4-dione
29. l-[(E)-3-(4-{[l-(2,3-Dihydro-benzofuran-5-yl)-ethylamino]-methyl}-2-methoxy-phenyl)- allyl]-pyrrolidine-2,5-dione
30. 3-[2-(4- { [(S)- 1 -(4-Chloro-phenyl)-ethylam ino] -methyl } -2-methoxy-phenoxy)-ethy 1] - oxazol idine-2,4-dione
31. 3-[2-(4-{ [(S)- 1 -(4-Chloro-phenyl)-ethylamino]-methyl}-2-methoxy-phenoxy)-ethyl]- 1 - methyl- 1 H-pyrimidine-2,4-dione
32. 1 -[2-(4-{ [l-(2,3-Dihydro-benzofuran-5-yl)-ethylamino]-methyl}-2-methoxy-phenoxy)- ethyl]-piperidine-2,6-dione
33. 3-[2-(4-{[(S)-l -(4-Chloro-phenyl)-ethylamino]-methyl}-2-methyl-phenoxy)-ethyl]-l- methyl-imidazolidine-2,4-dione
34. l-[3-(4-{[l-(2,3-Dihydro-benzofuran-5-yl)-ethylamino]-methyl}-2-methoxy-phenyl)- propyl]-pyrrolidine-2,5-dione
35. 1 -(2-{4-[(5-Chloro-6-methyl-indan- 1 -ylamino)-methyl]-2-methoxy-phenoxy}-ethyl)- pyrrolidine-2,5-dione
36. l-(2-{4-[(5-Chloro-4-methyl-indan-l-ylamino)-methyl]-2-methoxy-phenoxy}-ethyl)- pyrrolidine-2,5-dione
37. l-(3-{4-[(5-Chloro-indan-l-ylamino)-methyl]-2-methoxy-phenyl}-propyl)-pyrrolidine- 2,5-dione
38. 1 -(3- {4- [((S)-5 -Chloro-indan- 1 -ylamino)-methyl] -2-methoxy-phenyl } -propyl)- pyrrolidine-2,5-dione
39. l-(3-{4-[((R)-5-Chloro-indan-l-ylamino)-methyl]-2-methoxy-phenyl}-propyl)- pyrrolidine-2,5-dione
40. l-[3-(2-Chloro-4-{[l-(2,3-dihydro-benzofuran-5-yl)-ethylamino]-methyl}-phenyl)- propyl]-pyrrolidine-2,5-dione 41. 3-(2-{4-[(5-Chloro-indan- 1 -ylamino)-methyl]-2-methoxy-phenoxy}-ethyl)- 1 -methyl- 1H- pyrimidine-2,4-dione
42. l-[2-(4-{[l-(2,3-Dihydro-benzofuran-5-yl)-ethylamino]-methyl}-2-methoxy-phenyl)- cyclopropylmethyl]-pyrrolidine-2,5-dione
43. 3-(3-{4-[(5-Chloro-indan-l-ylamino)-methyl]-2-methoxy-phenyl}-propyl)-l-methyl- imidazol idine-2,4-dione
44. 3-[3-(4- { [(S)- 1 -(4-Chloro-phenyl)-ethylamino] -methyl } -2-methoxy-phenyl)-propyl]- 1 - methyl-imidazolidine-2,4-dione
45. 3-(2-{4-[(5-Chloro-indan-l-ylamino)-methyl]-2-methoxy-phenoxy}-ethyl)-l-methyl- imidazolidine-2,4-dione
46. 3 -[2-(4- { [(S)- 1 -(4-Chloro-phenyl)-ethylamino] -methyl } -2-methoxy-phenoxy)-ethyl] - 1 - methyl-imidazolidine-2,4-dione
47. l-[3-(4-{[(S)-l-(4-Chloro-phenyl)-ethylamino]-methyl}-2-methyl-phenyl)-propyl]- pyrrolidine-2,5-dione
48. l-[3-(4-{[(S)-l-(4-Chloro-phenyl)-ethylamino]-methyl}-2-methoxy-phenyl)-prop-2- ynyl]-pyrrolidme-2,5-dione
49. l -[3-(4-{[(S)-l-(4-Chloro-phenyl)-ethylamino]-methyl}-2-methoxy-phenyl)-propyl]- pyrrolidine-2,5-dione
50. 3-(2-{4-[(5-Chloro-indan-l-ylamino)-methyl]-2-methyl-phenoxy}-ethyl)-l -methyl- imidazolidine-2,4-dione
51. 3-[2-(4-{ [(S)- 1 -(4-Chloro-phenyl)-ethylamino] -methyl } -2-methyl-phenoxy)-ethyl]- 1 - methyl- lH-pyrimidine-2,4-dione
52. 3-[2-(4-{ [1 -(2,3-Dihydro-benzofiiran-5-yl)-ethylamino]-methyl}-2-methoxy-phenoxy)- ethyl]- 1 -methyl- 1 H-pyrimidine-2,4-dione
53. 3 -[2-(4- { [ 1 -(2,3 -Dihydro-benzofuran-5-yl)-ethylamino] -methyl } -2-methyl-phenoxy)- ethyl] - 1 -methyl- 1 H-pyrimidine-2,4-dione
54. 4-(l-{4-[2-(2,5-Dioxo-pyrrolidin-l-yl)-ethoxy]-3-methyl-benzylamino}-ethyl)- benzonitrile
55. 4-(l-{3-Methoxy-4-[2-(3-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-l-yl)-ethoxy]- benzylamino } -ethyl)-benzonitrile 56. l-[2-(4-{[l-(4-Chloro-phenyl)-propylamino]-methyl}-2-methoxy-phenoxy)-ethyl]- pyrrolidine-2,5-dione
57. 3-[2-(4-{[l-(4-Chloro-phenyl)-propylamino]-methyl}-2-methyl-phenoxy)-ethyl]-l- methyl- 1 H-pyrimidine-2,4-dione
58. 3-[2-(4-{ [ 1 -(4-Chloro-phenyl)-propylamino]-methyl } -2-methoxy-phenoxy)-ethyl]- 1 - methyl-imidazolidine-2,4-dione
59. l-[3-(4-{[l-(2,3-Dihydro-benzofuran-5-yl)-propylamino]-methyl}-2-methoxy-phenyl)- propyl] -pyrrolidine-2,5 -dione
60. 3 -[2-(4- { [ 1 -(4-Chloro-phenyl)-propylamino]-methy 1 } -2-methoxy-phenoxy)-ethyl] - 1 - methyl-imidazolidine-2,4-dione
61. 3-[2-(4- { [ 1 -(4-Chloro-phenyl)-propylamino]-methyl } -2-methoxy-phenoxy)-ethyl]- 1 - methyl- 1 H-pyrimidine-2,4-dione
62. l-[2-(4-{[l-(2,3-Dihydro-benzofuran-5-yl)-propylamino]-methyl}-2-methyl-phenoxy)- ethyl] -pyrrol idine-2,5 -dione
63. 3-[2-(4-{ [ 1 -(4-Chloro-phenyl)-propylamino]-methyl} -2-methyl-phenoxy)-ethyl]- 1 - methy l-imidazolidine-2 ,4-dione
64. l-(2-{4-[((S)-5-Chloro-indan-l -ylamino)-methyl]-2-ethyl-phenoxy}-ethyl)-pyrrolidine- 2,5-dione
65. 1 -(2- {4- [((S)-5 -Chloro-indan- 1 -ylamino)-methy 1] -2-fl uoro-phenoxy } -ethyl)-pyrrolidine- 2,5-dione
66. 1 -[2-(4-{[(S)-l -(4-Chloro-phenyl)-ethylamino]-methyl}-2-fluoro-phenoxy)-ethyl]- pyrrolidine-2,5-dione
67. l-(2-{4-[((S)-5,6-Dichloro-indan-l-ylamino)-methyl]-2-methoxy-phenoxy}-ethyl)- pyrrolidine-2,5-dione
68. l-[2-(4-{[(S)-l -(4-Chloro-phenyl)-ethylamino] -methyl } -2-ethyl-phenoxy)-ethyl] - pyrrolidine-2,5 -dione
69. l-[2-(4-{[l-(2,3-Dihydro-benzofuran-5-yl)-ethylamino]-methyl}-2-ethyl-phenoxy)- ethyl]-pyrrolidine-2,5-dione
70. 1 - [2-(4- { [ 1 -(3 ,4-Dichloro-phenyl)-ethylamino] -methyl } -2-methoxy-phenoxy)-ethyl] - pyrrolidine-2,5-dione 71. 1 -[2-(4-{ [1 -(3,4-Dichloro-phenyl)-ethylamino]-methyl}-2-methyl-phenoxy)-ethyl]- pyrrolidine-2,5-dione
72. l-[2-(4-{[(S)-l-(4-Chloro-phenyl)-ethylamino]-methyl}-phenoxy)-ethyl]-pyrrolidine-2,5- dione
73. 3-[2-(4-{[l-(3,4-Dichloro-phenyl)-ethylamino]-methyl}-2-methyl-phenoxy)-ethyl]-l- methyl-imidazolidine-2,4-dione
74. l-[2-(4-{[l-(4-Ethyl-phenyl)-ethylamino]-methyl}-2-methoxy-phenoxy)-ethyl]- pyrrolidine-2,5-dione
75. l-[2-(4-{[l -(4-Chloro-3-fluoro-phenyl)-ethylamino]-methyl}-2-methoxy-phenoxy)- ethyl]-pyrrolidine-2,5-dione
76. l-(2-{2-Methyl-4-[(l-p-tolyl-ethylamino)-methyl]-phenoxy}-ethyl)-pyrrolidine-2,5-dione
77. l-(2-{2-Methoxy-4-[(l-p-tolyl-ethylamino)-methyl]-phenoxy}-ethyl)-pyrrolidine-2,5- dione
78. l-[2-(4-{[(S)-l-(4-Chloro-phenyl)-ethylamino]-methyl}-2-hydroxymethyl-phenoxy)- ethyl]-pyrrolidine-2,5-dione
79. -(2-{4-[((S)-4,5-Dichloro-indan-l-ylamino)-methyl]-2-ethyl-phenoxy}-ethyl)-pyrrolidine- 2,5-dione
80. l-[2-(4-{[(S)-l-(4-Chloro-phenyl)-ethylamino]-methyl}-2-methoxy-phenylsulfanyl)- ethyl] -pyrrolidine-2,5 -dione
81. l-(2-{4-[((S)-5-Chloro-indan-l -ylamino)-methyl]-2-methoxy-phenylsulfanyl}-ethyl)- pyrrolidine-2,5-dione
82. l-[2-(4-{[l-(4-Chloro-3-fluoro-phenyl)-ethylamino]-methyl}-2-ethyl-phenoxy)-ethyl]- pyrrolidine-2,5-dione
83. 1 -[2-(4-{ [(R)- 1 -(4-Chloro-3-fluoro-phenyl)-ethylamino]-methyl} -2-ethyl-phenoxy)- ethyl]-pyrrolidine-2,5-dione
84. l-[2-(4-{[(S)-l-(4-Chloro-3-fluoro-phenyl)-ethylamino]-methyl}-2-ethyl-phenoxy)- ethyl]-pyrrolidine-2,5-dione
85. l-[2-(4-{[l-(4-Chloro-3-fluoro-phenyl)-ethylamino]-methyl}-2-fluoro-phenoxy)-ethyl]- pyrrolidine-2,5-dione
86. 1 -(2-{4-[(4-Chloro-5-fluoro-indan-l-ylamino)-methyl]-2-methoxy-phenoxy}-ethyl)- pyrrolidine-2,5-dione 87. l-(2-{4-[(6-Chloro-5-fluoro-indan-l-ylamino)-methyl]-2-methoxy-phenoxy}-ethyl)- pyrrolidine-2,5-dione
88. 1 -(2-{4-[(6-Chloro-5-fluoro-indan-l -ylamino)-methyl]-2-ethyl-phenoxy}-ethyl)- pyrrolidine-2,5-dione
89. l-(2-{4-[(4-Chloro-5-fluoro-indan-l-ylamino)-methyl]-2-ethyl-phenoxy}-ethyl)- pyrrolidine-2,5-dione
90. l-(2-{4-[(6-Chloro-5-fluoro-indan-l -ylamino)-methyl]-2-fluoro-phenoxy}-ethyl)- pyrrolidine-2,5-dione
91. l-(2-{4-[(5-Chloro-6-fluoro-indan-l-ylamino)-methyl]-2-methoxy-phenoxy}-ethyl)- pyrrolidine-2,5-dione
92. l-[2-(4-{[(R)-l-(2,3-Dihydro-benzofuran-5-yl)-ethylamino]-methyl}-2-methoxy- phenoxy)-ethyl]-pyrrolidine-2,5-dione
93. l-[2-(4-{[(S)-l-(2,3-Dihydro-benzoruran-5-yl)-ethylamino]-methyl}-2-methoxy- phenoxy)-ethyl]-pyrrolidine-2,5-dione.
General procedures:
Starting materials and solvents used in the synthesis are obtained from chemical vendors such as ABCR, Aldrich, Acros, Apollo, Fluka, Netchem, Lancaster and others.
The crude product is purified by column chromatography or flash chromatography.
In first step the appropriate benzaldehydes (4 = 4a-f) are synthesized in different way depending on the side chain of dioxoamide derivatives as described on Scheme 1.
The synthesis of compound formula 4a, wherein X represents -0-CH2- or -S-CH2-, is done by alkylation of 4-hydroxy- or 4-mercapto-benzaldehydes 6a with dibromoethane and dioxoamide (route via 6a% 7a') or bromo-ethyldioxoamide derivatives (route via 7a) in the presence of a base, preferably K2C03, TEA or sodium hydride using acetonitrile, DMF or MEK as solvent. Compounds of formula 4f, wherein X represents -CH2-0- or -CH2-S- , can be prepared analogously by alkylation of the corresponding benzyl alcohols or benzyl thiols of formula 6d with dibromomethane and dioxoamide (route via 6d', 7c') or bromo- methyldioxoamide derivatives (route via 7c) in the presence of a base, preferably K2C03, TEA or sodium hydride using acetonitrile, DMF or MEK as solvent An unsaturated compound of formula 4b, wherein X represents -C≡C-, can be synthesized in a Sonogashira reaction (Sonogashira, . et al. Tetrahedron Lett. 1975, 16 (50), 4467) and an unsaturated compound of formula 4d, wherein X represents -CH=CH-, can be synthesized in a Suzuki coupling (Suzuki, A. Tetrahedron Lett. 1979, 20 (36), 3437) followed by hydrolysis of the resulted compound of formula 4d'. A compound of formula 4c, wherein X represents -CH2- CH2-, can be prepared by hydrogenation of the corresponding compound of formula 4b or 4d'. A compound of formula 4e, wherein X represents -CH(CH2)CH- can be synthesized from the corresponding protected allylic derivative of formula 4d' using diazomethane (Scheme 1).
Scheme 1
Then the benzaldehydes 4 are reacted with different primary amines 5 in mild reductive amination conditions (NaBH(OAc)3 in THF or 2-picoline borane complex in EtOH). The resulted secondary amines 2 are reacted with different formyl- (R': -CHO) or oxo- (R': =0) cycloalkane carboxylic acid esters 3 in a repeated reductive amination step. The resulted esters (1, R=Me, Et) are optionally hydrolyzed in acidic conditions. The crude 1 is purified by chromatography, crystallization or via salt formation (Scheme 2).
Scheme 2
Starting materials of formula 3, 5 and 7 are commercially available or can be prepared by known methods. Compounds of formula 6 are commercially available (6a) or can be prepared by known methods. Compounds of formula 6b can be synthesized with tryflation of the corresponding alcohol. A compound of formula 6c is a protected derivative of an aldehyde of formula 6a with ethyleneglycol. A compound of formula 6d can be synthesized from commercially available benzoic acid derivatives by known method (Scheme 3).
Scheme 3
As mentioned above the compounds of formula 1 or a pharmaceutically acceptable salt, stereoisomer or a pharmaceutically acceptable salt of the stereoisomer can be used as active ingredient of a medicament in the preventive and/or therapeutic treatment of a CXCR3 receptor mediated disease or disorder, especially of a disease or disorder selected from the group consisting of COPD, psoriasis, graft/transplant rejection, ophthalmological disease, celiac disease, inflammatory bowel disease (IBD), type 1 diabetes, myasthenia gravis (MG), multiple sclerosis (MS) and other neuroinflammatory diseases, lupus, rheumatoid arthritis (RA) or lichen planus.
As the active ingredient of the medicament of the present invention, a substance may be used which is selected from the group consisting of the compound represented by the aforementioned formula 1 and pharmacologically acceptable salts, or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer. The substance, per se, may be administered as the medicament of the present invention, however, it is desirable to administer the medicament in a form of a pharmaceutical composition which comprises the aforementioned substance as an active ingredient and one or more pharmaceutical additives. As the active ingredient of the medicament of the present invention, two or more of the aforementioned substances may be used in combination. The type of pharmaceutical composition is not particularly limited, and the composition may be provided as any formulation for oral or parenteral administration. For example, the pharmaceutical composition may be formulated, for example, in the form of pharmaceutical compositions for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, solutions and the like, or in the form of pharmaceutical compositions for parenteral administrations such as injections for intravenous, intramuscular, or subcutaneous administration, drip infusions, transdermal preparations, transmucosal preparations, nasal drops, inhalants, suppositories and the like. Injections or drip infusions may be prepared as powdery preparations such as in the form of lyophilized preparations, and may be used by dissolving just before use in an appropriate aqueous medium such as physiological saline.
Types of pharmaceutical additives used for the manufacture of the pharmaceutical composition, content ratios of the pharmaceutical additives relative to the active ingredient, and methods for preparing the pharmaceutical composition may be appropriately chosen by those skilled in the art. Inorganic or organic substances, or solid or liquid substances may be used as pharmaceutical additives. Generally, the pharmaceutical additives may be incorporated in a ratio ranging from 1 % by weight to 90% by weight based on the weight of an active ingredient.
The dose and frequency of administration of the medicament of the present invention are not particularly limited, and they may be appropriately chosen depending on conditions such as a purpose of preventive and/or therapeutic treatment, a type of a disease, the body weight or age of a patient, severity of a disease and the like. Generally, a daily dose for oral administration to an adult may be 0.01 to 1 ,000 mg (the weight of an active ingredient), and the dose may be administered once a day or several times a day as divided portions, or once in several days. When the medicament is used as an injection, administrations may preferably be performed continuously or intermittently in a daily dose of 0.001 to 100 mg (the weight of an active ingredient) to an adult.
The present invention will be explained more specifically with reference to the following examples, however, the scope of the present invention is not limited to these examples.
Unless otherwise stated, the following abbreviations have the stated meanings in the examples below: abs. = absolute
AcOH = Acetic acid
[(C6H5)3P]2PdCl2 = Bis(triphenylphosphine)palladium(II) dichloride
cc. HC1 = concentrated hydrogen chloride solution
Cul = copperl iodide
DCM = dichloromethane
Diazald = N-methyl-N-nitroso-p-toluenesulfonamide
DMF = N,N-dimethylformamide equiv. = equivalent
Et = ethyl
EtOH - ethanol
Et20 = diethyl ether
EtOAc = ethyl acetate
HCCOH = formic acid
HPLC = high performance liquid chromatography
Ipam = isopropyl amine
K2C03 = potassium carbonate
K P04 = potassium phosphate
KBr = potassium bromide
OH = potassium hydroxyde
LC/MS = liquid chromatography - mass spectrometry
MEK = methyl -ethyl ketone
Me = methyl
MeOH = methanol
NaHC03 = sodium bicarbonate
Na2S04 = sodium sulfate
NaBH(OAc)3 = sodium triacetoxy borohydride
nM = nanomole
NaOH = sodium hydroxyde
NMR = nuclear magnetic spectroscopy
Pd(OAc)2 = palladium(II) acetate
r.t. = room temperature
TBAB = tetrabutylammonium bromide
TEA = triethylamine
THF = tetrahydrofurane
TsOH = p-toluenesulfonic acid monohydrate Analitical LC/MS is performed using Waters Alliance 2695 + 2996 PDA at 220 nm. A system) MS: Waters LCT Premier XE; Column: Atlantis dC 18 (3 μιη) 2.1x50mm; flow 0.7 ml/min of acetonitrile/water/0.05% TFA gradient in ESI+ mode
B system) MS: Micromass ZQ; Column: Purospher-STAR RP18e (3 μιη) 4.6x55mm; flow 1.6 ml/min of water/acetonitril/20mM NH4OH gradient or Xterra MS-C18 (3.5 μΜ) 2.1x50mm; flow: 1.0 ml/min of water/acetonitril/20mM NH4OH gradient in ESI+ mode.
Preparative chiral HPLC is performed using Berger Prep SFC at 210 nm;
C system) Column: Chiralpack IC 250 x 21 mm (5μπι) Flow: 50 ml/min; CO2/[Ethanol/+0.5%Ipam] 60% / 40% (other circumstances are detailed in examples). For structural confirmation NMR spesctra are measured for all compounds as well. The
NMR spectra are recorded on a Bruker Advance II 400 MHz spectrometer at ambient temperature in DMSO- 6 solution. The chemical shifts are referred to tetramethylsilane (δ, ppm). In some cases not only Ή but 13C, ed-HSQC, zqs-TOCSY and HMBC spectra are also recorded. Precursor preparations
Intermediate 4.1 4-[2-(2,5-Dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzaldehyde
A method: 6.85 g (45 mmol) of vanilline (6.1) and 10.2 g (49.5 mmol) l-(2-bromo-ethyl)- pyrrolidine-2,5-dione (7.1) is heated with 8.28 g (60 mmol) K2C03 in 200 ml of acetonitrile under reflux for 15 h. Precipitated Br is filtered off, the filtrate is evaporated, the residue is dissolved in 200 ml of dichloromethane, washed with water and 2N NaOH solution, dried with Na2S04 and evaporated. The remaining oil is triturated with «-hexane to result the desired 4.1 in white crystals. Yield: 6.88 g (55%). (M+H)+ = 278, Rt (A)= 1.90 min, purity 97.6%.
Ή-NMR: 2.64 (s, 4H), 3.77 (t, 2H), 2.75 (s, 3H), 4.21 (t, 3H), 7.17 (d,lH), 7.40 (d, 1H), 7.53 (dd, 1H), 9.84 (s,lH).
B method: 1 1.66 g (45 mmol) of 4-(2-bromo-ethoxy)-3-methoxy-benzaldehyde (6.2) and 4.46 g (45 mmol) pyrrolidine-2,5-dione (7.2) is heated with 8.28 g (60 mmol) K2C03 in 200 ml of acetonitrile for 8 h. After same isolation procedure as in A method 4.1 is given with same purity.
Following the procedure as outlined for intermediate 4.1, the intermediates of general formula 4a listed in Table 1 are prepared.
TABLE 1
Rt Purity
Intermediate Structure (M+H)+
min. (system) (%)
262 2.25 (A) 98.2
4.2
276 2.45 (A) 98.3
4.3
282 2.26 (A) 98.3
4.4
266 3.36 (B) 99.3
4.5
278 1.69 (A) 86.7
4.6
248 1.98 (A) 95.9
4.7
Intermediate 4.18 4-[(E)-3-(2,5-Dioxo-pyrrolidin-l-yl)-propenyl]-3-methoxy-benzaldehyde
Step 1: 6.85 g (45 mmol) vanilline (6.1) is cooled in a 100 ml of a mixture of DCM- pyridine 4:1, then 9.1 ml (54 mmol) of trifluoromethanesulfonic anhydride in 10 ml DCM is dropped in. The mixture is stirred at r.t. for 2 hours, after evaporated and the residue is triturated with 3 x 10 ml of EtOAc, the collected organic layer is dried and evaporated. The crude material (6.1a) is used for next step without further purification.
Intermediate 4.18
Step 2: The formed crude trifluoro-methanesulfonic acid 4-formyl-2-methoxy-phenyl ester (6.1a), 2.52 ml (45 mmol) of ethylene glycol and 0.77 g (4.5 mmol) TsOH are refluxed in 180 ml of benzene. After evaporation the residue is purified by column chromatography. The desired intermediate is 1 1 g (80%) of trifluoro-methanesulfonic acid 4-[l,3]dioxolan-2-yl-2- methoxy-phenyl ester (6.1b), as a yellow oil. (M+H)+ = 329, Rt (A)= 3.44 min, purity 93.4%.
Step 3: A mixture of 1.76 g (5 mmol) triflate (6.1a), 2.1 g (15 mmol) of 1-allyl- pyrrolidine-2,5-dione (7.3; Bull.Chem. Soc. Japan, 1984, 57(10), 3021), 0.067 g (0.3 mmol) of Pd(OAc)2, 0.373 g (5 mmol) KC1, 3.22 g (10 mmol) TBAB and 2.12 g (10 mmol) K3P04 is hetaed in 10 ml DMF under nitrogen at 120°C for 8 h. The mixture is diluted with water, extracted with 3x50 ml of EtOAc, the collected organic phase is evaporated and purified by column chromatography (EtOAc - «-hexane 1 : 1). The desired intermediate (4.18a) is 1.8 g of 1- [(E)-3-(4-[l ,3]dioxolan-2-yl-2-methoxy-phenyl)-allyl]-pyrrolidine-2,5-dione, as an oil. (M+H)+ = 318, Rt (A)= 2.58 min, Rt (B) = 4.15 min, purity 71%.
Step 4: 1.8 g (4 mmol) of protected aldehyde (4.18a) and 5 ml (30 mmol) of cc. HCI in 15 ml of dioxane are stirred at r.t. for 3 h. After evaporation and purification by flash chromatography the desired 4-[(E)-3-(2,5-dioxo-pyrrolidin-l-yl)-propenyl]-3-methoxy- benzaldehyde (Intermediate 4.18) is 0.5 g (46%) as an oil. (M+H)+ = 274, Rt = 2.56 min (A), purity 91.2%.
1H-NMR: 2.67 (s, 4H), 3.90 (s, 3H), 4.16 (d, 2H), 6.37 (dt, 1H), 6.79 (d, 1H), 7.47-7.50 (m, 2H), 7.67 (d, 1H), 9.95 (s,l H).
Intermediate 4.19 4-[3-(2,5-Dioxo-pyrrolidin-l-yl)-prop-l-ynyl]-3-methoxy-benzaldehyde
6.1b 7.4 Intermediate 4.19
A mixture of 4.26 g (15 mmol) triflate (6.1b), 2.47 g (18 mmol) of -prop-2-ynyl- pyrrolidine-2,5-dione (7.4), 0.067 g (0.3 mmol) of [(C6H5)3P]2PdCl2, 0.143 g (0.75 mmol) Cul, 0.32 g (0.75 mmol) of l,4-bis(diphenyl-phosphino)butane and 7 ml (50.5 mmol) of TEA in 40 ml DMF under nitrogen at 100°C for 3 h. The inorganic salts are removed and DMF is evaporated. The residue is treated with water, extracted 3x50 ml of EtOAc, the collected organic phase is evaporated and purified by flash chromatography (toluene - MeOH 9: 1). The desired intermediate 4.19 is 1.9 g (44%) of 4-[3-(2,5-dioxo-pyrrolidin-l-yl)-prop-l-ynyl]-3-methoxy- benzaldehyde, as a dark yellow solid. (M+H)+ = 272, R, = 2.15 min (A), purity: 98.9%.
Ή-NMR: 2.71 (s, 4H), 3.89 (s, 3H), 4.44 (s, 2H), 7.47-7.50 (m, 2H), 7.55 (d, 1H), 9.98
(s,l H).
Following procedures outlined for intermediate 4.19 the intermediates of general formula 4b listed in Table 2 are prepared.
TABLE 2
Intermediate 4.23 4-[3-(2,5-Dioxo-pyrrolidin- 1 -yl)-propyl]-3-methoxy-benzaldehyde
Intermediate 4.19 A method: Using 3.02 g (9.2 mmol) of triflate (6.1b) a crude protected allyl derivative (4.18a) is formed (as described in step2 and 3 of Intermediate 4.18), which is hydrogenated by H-Cube equipment in full-H2 mode in EtOAc. After evaporation the residue is dissolved in 50 ml of dioxane and stirred with 10 ml of cc. HCl at r.t. for 0.5 h. The mixture is evaporated, the residue is diluted with water, extracted with ethylacetate, dried and removed the solvent. The crude material is purified by flash chromatography. The desired product (Intermediate 4.23) is 1.65 g (65.3%). (M+H)+ = 276, Rt = 2.57 min (A), purity: 97.7%.
1H-NMR: 1.75 (qv, 2H), 2.59-2.62 (m, 6H), 3.38 (t, 2H), 3.86 (s, 3H), 7.40 (d, 2H), 7.47 (dd, 1H), 9.94 (S, 1H).
B method: Hydrogenation of 4-[3-(2,5-Dioxo-pyrrolidin-l-yl)-prop-l-ynyl]-3-methoxy- benzaldehyde (Intermediate 4.19) in same circumstances as described in A method is resulted Intermediate 4.23 in one step. The yield and purity is same as in A method. Following procedures outlined for intermediate 4.23 the intermediate compounds of general formula 4c listed in Table 3 are prepared.
TABLE 3
Intermediate 4.27 4-[2-(2,5-Dioxo-pyrrolidin-l-ylmethyl)-cyclopropyl]-3-methoxy- benzaldehyde
Diazomethane is generated with a diazomethane-generating kit (Aldrich): a solution of 3.846 g (17.9 mmol) of Diazald in 24 ml of Et20 is added drop wise to a mixture of 3.018 g (53.78 mmol) of OH in 18 ml of water, 4 ml of diethyl ether and 18 ml of 2-(2-ethoxyethoxy)- ethanol at 70 °C. The etheral solution of diazomethane is continuously distilled into a stirred solution of 575 mg (1.81 mmol) of protected aldehydes (4.18a; as described in step3 of Intermediate 4.19) and 3.6 mg (0.016 mmol) Pd(OAc)2 in a mixture of DCM and Et20 (28 ml / 20 ml) kept at 70 °C. After the addition of diazomethane is complete the solution is stirred at r.t. for 30 min. The excess of diazomethane is quenched with AcOH. The resulted mixture is washed with AcOH, saturated Na2C03 solution, dried and evaporated. The yield is 514 (95%) mg of titled compound. (M+H)+ = 276, Rt = 2.58 min (A), purity: 99.9%,
EXAMPLES
Example 1 /rfl is-4-[([l-(2,3-Dihydro-l-benzofuran-5-yl)ethyl] {4-[2-(2,5-dioxo-pyrrolidin- l-yI)ethoxy]-3-methoxybenzyl}amino)methyl]cyclohexanecarboxylic acid
Step 1: 3.59 g (22 mmol) of l-(2,3-dihydro-benzofuran-5-yl)-ethylamine (5.1), 5.54 g (20 mmol) of intermediate 4.1 and 1.60 ml (28 mmol) of AcOH are dissolved in 200 mL of THF, then 12.7 g (60 mmol) of NaHB(OAc)3 is added in small portions into the solution at room temperature. The formed suspension is stirred overnight, and then diluted with 200 ml of EtOAc and 400 mL of water. After separation the aqueous phase is washed EtOAc, the combined organic phase is dried and evaporated. The crude oil is purified with flash chromatography (up 10% MeOH in DCM). The intermediate (2.1) is 7.05 g pale yellow oil (83%); (M+H)+ = 425, R,= 2.1 min (A), purity: 96.4%.
Salt formation: 1 18 mg (0.28 mmol) of 2.1 and 100 mg (0.28 mmol) of 1.5- naphthalenedisulfonic acid tetrahydrate is dissolved in 2 ml of EtOH, then evaporated, the residue is treated with Et20 and the formed white solid filtrated, and washed with Et20. Yield is 80 mg (48%) 2.1 with 0.6 moles 1,5-naphthalenedisulfonic acid. (M+H)+ = 425, Rt = 2.1 min (A), purity: 98.
Step 2: 950 mg (2.24 mmol) of free amine (2.1) and 1.14 g (6.72 mmol) of trara-4-formyl- cyclohexanecarboxylic acid ethyl ester (3.1) are dissolved in THF and 0.19 mL (3.36 mmol) of AcOH is added followed by the addition 2.37 g (1 1.19 mmol) of NaHB(OAc)3 and the reaction is stirred overnight at room temperature. Then the reaction is diluted EtOAc (75 ml) and water (50 ml) and 2 ml IN HC1 is added. The aqueous phase is separated, the organic phase is extracted two times with the same amounts of water and IN HC1 solution. The aqueous phases are combined, the pH adjusted to 8-9 by the addition of IN NaOH and extracted two times with EtOAc. The combined organic phase is washed with brine, dried and evaporated. The crude product is used for next step without purification. Yield is 1.21 g of 1.1 (93.4%) as an oil. (M+H)+ = 593; Rt = 2.78 min (A), purity: 91.1%.
Salt formation: 250 mg (0.44 mmol) of 1.1 is dissolved 1 ml of THF and acidified with HCl in Et20. The precipitated HCl salt is filtrated, washed Et20 and dried. Yield is 185 mg (66.4%) as a white foam. (M+H)+ = 593; Rt = 2.78 min (A), purity 93.3%.
Step 3: 1.21 g (2.1 mmol) of ester (1.1) is dissolved in 5 ml of dioxane, 5.23 ml (10.5 mmol) of 2N HCl is added in and the mixture was stirred at 60°C for 3 hours. Then the mixture is diluted with water, the pH value is adjusted to 7 with IN NaOH and the aqueous phase is extracted 3 times with DCM. Organic phases were combined, dried and evaporated. The title compound is isolated as a white foam after HPLC purification using 4% MeOH in DCM. Yield 615 mg (52%); Molecular Formula (M+H)+ = 565, Rt = 2.35 min (A), purity 98.1%.
Ή-NMR: 0.6 (dddd, IH), 0.7 (dddd, IH), 1.23 (ddd, 2H), 1.28 (d, 3H), 1.4 (br, I H), 1.82 (d, I H), 1.83 (d, IH), 1.84 (d, IH), 1.85 (d, IH), 2.00 (dd, IH), 2.04 (dddd, I H), 2.25 (dd, IH), 2.63 (s, 4H), 3.16 (t, 2H), 3.27 (d,lH), 3.42 (d, I H), 3.70 (t, 2H), 3.71 (s, 3H), 3.79 (q, IH), 4.03 (t, 2H), 4.49 (t, 2H),6.70 (d, IH), 6.78 (dd, IH), 6.84 (d, IH), 6.90 (d, H), 7.04 (dd, IH), 7.20 (d, I H), 1 1.90 (s, IH).
Example 2 cw-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l- yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
Step 1: is undertaking as in Example 1, step 2 is accomplished with cw-4-formyl- cyclohexanecarboxylic acid methyl ester (3.2) in same conditions, after acidic hydrolysis and purification the title compound is isolated as a white foam. Molecular Formula
(M+H)+ = 565; Rt = 2.45 min (A), purity 99.5 %. Ή-NMR: 1.05-1.07 (m, 2H), 1.28 (d, 3H), 1.36-1.38 (m, 3H), 1.55 (m, 3H), 1.68 (m, IH), 2.07 (dd, IH), 2.25 (dd, IH), 2.35 (qi, IH), 2.63 (s, 4H), 3.15 (t, 2H), 3.28 (d,l H), 3.42 (d, IH), 3.70 (t, 2H), 3.71 (s, 3H), 3.78 (q, IH), 4.02 (t, 2H), 4.49 (t, 2H),6.69 (d, IH), 6.78 (dd, I H), 6.86 (d, IH), 6.90 (d, IH), 7.03 (dd, IH), 7.20 (d, IH), 1 1.89 (s, IH).
Example 3 / *a«s-4-[([(R)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxyIic acid
Chiral
61 1 mg of Example 1 is separated by preparative chiral column chromatography. The first eluted enantiomer has (./^-configuration, yield is 290 mg (95%). (M+H)+ = 565, Rt = 1 1.0 min. (C), purity: 98.1%. Example 4 /r ns-4-[([(5)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo- pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid Chiral
61 1 mg of Example 1 is separated by preparative chiral column chromatography. The second eluted enantiomer has (5)-configuration, yield is 240 mg (79%). (M+H)+ = 565, Rt = 12.2 min (C), purity: 99.2%. Example 5 i -a«s-4-[([(S)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
Chiral
Step 1 is undertaking as in Example 1 using (5)-l-(4-chloro-phenyl)-ethylamine (5.2), further steps are occurred analogously as in Example 1 and the desired compound is resulted. (M+H)+ = 557, Rt = 2.51 min (A), purity: 97.6 %.
Example 6 //•a is-4-[([(R)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
Chiral
Step 1 is undertaking as in Example 5 using ( ?)-l-(4-chloro-phenyl)-ethylamine (5.3), further steps are occurred analogously as in Example 1 and the desired compound is resulted. (M+H)+ = 557, Rt = 2.59 min (A), purity: 96.8 %. Example 7 /r is-4-[([(S)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methyl-benzyI}-amino)-methyl]-cyclohexanecarboxylic acid
Chiral
Step 1 is undertaking as in Example 1 using (S)-l-(4-chloro-phenyl)-ethylamine (5.2) and Intermediate 4.2, further steps are occurred analogously as in Example 1 and the desired compound is resulted. (M+H)+ = 541, Rt = 2.66 min (A), purity: 95.5 %.
Example 8 cw-4-[([(S)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methyl-benzyl}-amino)-methyl]-cycIohexanecarboxyIic acid
Chiral
Step 1 is undertaking as in Example 7, step 2 is accomplished with cw-4-f rmyl- cyclohexanecarboxylic acid methyl ester (3.2) in same conditions, after acidic hydrolysis and purification the title compound is isolated. ( +H)+ = 541 , Rt = 2.64 min (A), purity 98.0 %.
Example 9 /r /i5-4-[([(R)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
Chiral
Step 1 is undertaking as in Example 6 using (/?)-l -(4-chloro-phenyl)-ethylamine (5.3) and Intermediate 4.2, further steps are occurred analogously as in Example 6 and the desired compound is resulted. (M+H)+ = 541 , Rt = 2.61 min (A), purity: 96.8 %.
Example 10 //•a«s-4-[((5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl]-cyclohexane-carboxylic acid
Following procedures outlined in Example 1 using 5-chloro-indan-l -ylamine (5.4) and Intermediate 4.1 in the first reductive amination step, the desired compound is resulted. (M+H)+ = 569, Rt = 2.57 min (A), purity 89.9 %.
Example 11 ira«s,-4-[(((¾! -5-ChIoro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrroIidin-l-yl)-ethoxy]- 3-methoxy-benzyI}-amino)-methyl]-cyclohexanecarboxylic acid
643 mg of Example 10 is separated by preparative chiral column chromatography. The first eluted enantiomer has (^-configuration, yield is 250 mg (77.8%). (M+H)+ = 569, Rt = 6.6 min. (C), purity: 98.2%.
Example 12 ir «s-4-[(( 5 -5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]- 3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
Method A Following chiral separation procedures outlined in Example 11 using 643 mg of Example 10, 270 mg (84%) of the titled compound is isolated as a second eluted material. (M+H)+ = 569, R, = 9.0 min. (C), purity: 97.4%.
Method : Following procedures outlined in Example 1 using 400 mg (2.39 mmol) of (S)- 5-chloro-indan-l-ylamine (5.5) and 661 mg (2.39 mmol) of Intermediate 4.1 the titled compound is isolated: 652 mg (48%) (M+H)+ = 569, Rt = 2.69 min (A), purity 99.5 %. Example 13 ci$-4-[((5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl]-cyclohexane-carbox lic acid
Following procedures outlined in Example 2 using 5-chloro-indan-l -ylamine (5.4) and Intermediate 4.1 and 3.2 ester in reductive amination steps the desired compound is resulted. (M+H)+ = 569, Rt = 6.31 min (B), purity 85.6 %.
Example 14 /i-a«s-4-[(((5)-4,5-Dichloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid hydrochloride
Step 1 and 2: 3.70 g (15.5 mmol) of (S)-4,5-dichloro-indan-l-ylamine hydrochloride (5.6) is dissolved in DCM, washed with saturated sodium bicarbonate and brine, dried over sodium sulfate and evaporated at reduced pressure. The residue is dissolved in THF and placed into a water bath (bath temperature: 15°C). 4.29 g (15.5 mmol) of Intermediate 4.1 is added followed by the addition of acetic acid (1.33 ml; 23.3 mmol). 8.21 g (38.7 mmol) of NaBH(OAc)3 is added in four portions at 10 minutes intervals. Water bath is removed and the reaction is stirred one hour at room temperature. 2.63 g (15.5 mmol) of trara-4-formyl-cyclohexanecarboxylic acid methyl ester (3.3) is added and the reaction is stirred another hour at room temperature. Then the mixture is diluted with water, pH is adjusted to 7 by the addition of saturated NaHC03 and extracted with DCM three times. Organic phases are combined, dried over Na2S04 and evaporated at reduced pressure. The residue is purified by silica gel flash chromatography using 50% EtOAc in hexane. Evaporation of pure fractions resulted in a pale yellow oil. Yield: 6.40 g (67%), (M+H)+ = 317, Rt = 2.91 min (A). Purity: 98.6%
Step3: 6.40 g (10.4 mmol) of methyl ester is dissolved in 20 ml of dioxane. 25.9 ml (51.8 mmol) of 2N HC1 solution is added and the reaction was stirred for 5 hours at 80°C. Then the mixture is diluted with water, pH is adjusted to 7 by the addition of saturated NaHC03 and extracted with DCM three times. Organic phases are combined, dried over sodium sulfate and evaporated at reduced pressure. The residue is purified by silica gel flash chromatography using a gradient of 3 to 6 % of MeOH in DCM. Pure fractions are combined and evaporation resulted in a white solid foam of desired compound: 3.82 g (61.1%). (M+H)+ = 603, Rt = 2.66 min (A). Purity: 99.6%
Following the procedures as outlined in Example 1 using different amines (5), benzaldehydes (4) and formyl-cycloalkanecarboxylic acid esters (3, R' = CHO) the compounds listed in Table 4 are prepared.
TABLE 4
Rt Purity
Examples Structure (M+H)+
min. (system) (%)
15.
583 2.53 (A) 92.3
16. HO
569 2.48 (A) 97.8
38.
579 2.50 (A) 81 ,0
39. HO Chiral
556 2.68 (A) 96,3
40. HO ^
550 2.74 (A) 95.2
41. OH
5.5-8.6 (C)
565 no separation 97.0
42.
583 2.68 (A) 91.7
43.
583 2.67 (A) 91.0
44.
567 6.68 (B) 87.5 59.
592 2.55 (A) 96,9
60.
576 2.43 (A) 94,0
61.
532 2.26 (A) 95.9
62.
575 2.57 (A) 96.6
63.
571 2.30 (A) 95.0
64.
582 2.35 (A) 92.0
65.
555 2.38 (A) 90.0
73. HO
jt¾0 Chiral
545 2.49 (A 97.3
74. HO Chiral
603 2.61 (A) 93.1
75. HO CWral
555 2.69 (A) 98,2
76. o^
563 2.54 (A) 98.5
77. o^
591 2.58 (A) 94.6
78.
575 2.71 (A) 96.8
79. Chiral
527 2.48 (A) 99.2 Example 120 //•a«s-3-([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methoxy-4-[2-(3-methyl-
2,6-dioxo-3,6-dihydro-2H-pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-cycIobutanecarboxyIic acid
Step 1: 0.37 g (2.24 mmol) of l-(2,3-dihydro-benzofuran-5-yl)-ethylamine (5.1) and 0.62 g (2.054 mmol) of Intermediate 4.13 are dissolved in 10 ml of THF. 0.17 ml (3.06 mmol) of AcOH and 1.08 g (5.09 mmol) of NaHB(OAc)3 are added in and the reaction is stirred overnight. Then the mixture is diluted with water, pH adjusted to 8-9 with NaHC03 and it is extracted with EtOAc, the combined organic phase is washed water and brine, dried Na2S04 and evaporated. The intermediate of 2.2 is 0.88 g (95.6%).
(M+H)+ = 452, Rt = 2.24 min (A), purity: 86.7 %.
Step 2: 0.88 g (1.95 mmol) of formed secondary amine is dissolved in 15 ml of abs. EtOH, 0.334 g (2.92 mmol) of 3-oxo-cyclobutanecarboxylic acid (3.4), 0.17 ml (2.92 mmol) of AcOH and 0.313 g (2.92 mmol) of 2-picoline borane complex are added in. The mixture is stirred at 55°C overnight, then is cooled, evaporated, diluted with water and extracted with DCM. The combined organic phases is dried, evaporated and purified by column chromatography (CHCI3 - MeOH 19/1). The first eluted is the titled compound. 1 10 mg (10.3 %); (M+H)+ = 550, R, = 3.16 min(B), purity: 93,2 %.
Example 121 cw-3-([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methoxy-4-[2-(3-methyl-2,6- dioxo-3,6-dihydro-2H-pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-cycIobutanecarboxylic acid
During the column chromatography of Example 120 the second eluted is the titled compound: 510 mg (47.6 %); (M+H)+ = 550, Rt = 3.26 min (B), purity: 95.6%.
Example 122 cw-3-([(R)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methoxy-4-[2-(3- methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-l-yl)-ethoxy]-benzyl}-amino)- cyclobutanecarboxylic acid
375 mg (0.68 mmol) of Example 121 is separated by preparative chiral column chromatography (Berger SFC systems; Chiralcel OJ-H 250x21 mm column (5μΜ); 50 ml/min flow rate; C02/ 80%/20%; EtOH + 0.5% IP A). The first eluted enantiomer has (/^-configuration, yield is 124 mg (68%). (M+H)+ = 550, Rt = 10.7 min, purity: 100%. Example 123 c/s-3-([(S)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methoxy-4-[2-(3-methyi- 2,6-dioxo-3,6-dihydro-2H-pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-cyclobutanecarboxylic acid
375 mg (0.68 mmol) of Example 121 is separated by preparative chiral column chromatography (Berger SFC systems; Chiralcel OJ-H 250x21 mm column (5μΜ); 50 ml/min flow rate; C02/ 80%/20%; EtOH + 0.5% IPA). The second eluted enantiomer has (5)- configuration, yield is 125 mg (68%). (M+H)+ = 550, Rt = 12.6 min, purity: 99.9%. Example 124 /ra is-3-([l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l- yl)-ethoxy]-3-methyl-beniiyl}-amino)-cyclobutanecarboxylic acid
Step 1 is undertaking as in Example 120 using l-(4-chloro-3-fluoro-phenyl)-ethyl-amine (5.7) and (4.2) for the first reductive amination step. (M+H)+ = 419, Rt = 2.44 min (A), purity: 93.9 %.
Step 2: 2.73 g (6.5 mmol) of formed secondary amine is dissolved in 108 ml of THF, 1.487 g (2 equiv.) of 3-oxo-cyclobutanecarboxylic acid (3.4), 0.56 g (1.5 equiv.) of AcOH and 4.14 g (3 equiv.) of NaBH(OAc)3 are added in. The mixture is stirred at 35°C for 48 h, then is cooled, diluted with water and extracted with EtOAc. The combined organic layer is purified by column chromatography (CHC13 - MeOH 19/1). The first eluted material is the titled compound. 180 mg (5.3 %). (M+H)+ = 517, Rt = 4.69 min (B), purity: 96.5 %.
Example 125 cis-3-([l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy]-3-methyl-benzyl}-amino)-cycIobutanecarboxylic acid
From Example 124 after the column chromatography the second eluted material is the titled compound: 310 mg (9.2 %). (M+H)+ = 517, Rt = 4.70 min (B), purity: 99%.
Following the procedures as outlined in Example 121 using different amines (5), benzaldehydes (4) and oxo-cycloalkanecarboxylic acid esters (3, R' = O), or as outlined in Example 1 using different amines (5), benzaldehydes (4) and formyl-cycloalkanecarboxylic acid esters (3, R' = CHO) the compounds listed in Table 5 are prepared.
TABLE 5
Biological methods
Compounds according to the invention as described are useful to block the interaction of CXCR3-A and CXCL10 in a radiolabelled binding assay.
Competition radioligand binding assays were performed to determine the in vitro potency of the newly synthesized, unlabelled test compounds to displace the specific binding of the radiolabelled endogenous chemokine, 125I-CXCL10, from the human CXCR3-A receptor. IC50 values were determined for the test compounds and used to explore the structure-activity relationships (SAR). The established SAR was used to feed back the molecular design and to suggest some suitable modifications for groups and structural elements by which the affinity of test compounds for the human CXCR3 receptor would be improved. Cell line and membrane preparation
CHO cells stably expressing human recombinant CXCR3-A receptors were generated in Sanofi-Aventis (LIT Frankfurt) by transfection of Flp-In-CHO host cells with a plasmid construct of pCDA5-FRT-TO_IRES-Gai4qi4_DEST. This cell line was registered in Sanofi-Aventis cell line bank. Cells were grown in Ham's F12 (PAA) medium supplemented with 10% FCS (PAA, Cat No. El 5-898) and 0.6 % Hygromycin (PAA) in T175 flasks at 37°C in a humidified incubator under 5% CO 2, 95% air. Cells were harvested from the culture flasks by a short treatment (8-10 minutes) with Versene (Gibco, Cat No. 15040). Cell suspension was diluted with PBS and cells were collected with centrifugation at 230 g for 10 minutes at 10 °C with a Juan centrifuge. Pellets containing approximately 1 x 108 cells were resuspended in 15 ml of 20 mM HEPES pH=7.4, 10 mM EDTA buffer supplemented with complete protease inhibitor (Roche, Cat No. 1 1 697 498 001). This suspension was homogenized with a teflon/glass homogenizer (Sartorius potter S) with 3 x 10 sec pulses in ice cold water bath, and then centrifuged at 300 x g for 10 min at 4°C with a Sigma centrifuge. The supernatant was carefully collected and centrifuged at 100,000 x g for 60 min at 4° with a Beckman Avanti J30 centrifuge. The resulting pellet was washed once with 15 ml of fresh preparation buffer. The final membrane pellet was resuspended in storage buffer (20 mM HEPES pH=7.4, 0.1 mM EDTA, 250 mM sucrose supplemented with complete protease inhibitor) in a volume ratio of approximately 1 x 108 cells / 1 ml, which gave a protein concentration of 2 to 4 mg/ml. Protein concentration was determined with Bio-Rad protein assay (Cat No 500-0006). Membrane aliquots were stored at -80°C. No degradation was observed until a storage period of approximately 5 months.
125I-CXCL10 radioligand binding study
The composition of the binding assay buffer was determined in a course of detailed optimization procedure. This resulted in a binding assay buffer constituted by the following components: 25 mM Hepes (pH=7.4), 5 mM MgCl2, 1 mM CaCl2, 100 mM NaCl, supplemented with 0.1% of protease free BSA (as a final concentration). Competition binding assay was performed using 125I-CXCL10 (PerkinElmer, NEX348, specific activity 2200 Ci/mmol) radioligand in a final concentration of 50-70 pM. The nonspecific binding was defined by 150 pM of hr-CXCLlO (R&D Systems, Cat No 266-IP). The total assay volume was equal to 150 μΐ and contained 0.1% of DMSO (final concentration). Binding reaction was initiated by adding of membranes (10-20 μg proteins, approximately 5 x 105 cell equivalents) to the reaction mixture. After 60 minutes of incubation at 25°C the reaction was terminated by rapid filtration over GF/B glass fibre filters that were pre-soaked with 0.5% poliethylenimine (Fluka Analytical, P3143) for 1 hour, using a Skatron cell harvester device. Filters then were washed with 8 ml of ice-cold wash buffer (modified binding buffer in which BSA was omitted and the concentration of NaCl was adjusted to 500 mM concentration). The radioactivity retained on the filters was measured by a Wizard 1470 Automatic Gamma counter.
Test compounds were dissolved prior to the binding assay at a concentration of 10 mM in
DMSO. Stock solutions were stored at -20°C for not longer than 3 months. On the day of binding assay serial dilutions of test compounds ranging from 10 mM up to 3 x 10"7 M (or 3 x 10"9 M) were generated by 8 (or 12) consecutive steps using DMSO as solvent. Before adding these solutions of test compound to the binding reaction mixture, an intermediate dilution procedure was applied, in which 30 μΐ of each solution sample was transferred into a dilution tube containing 970 μΐ of binding assay buffer. Then 50 μΐ of these second dilution series was added to the test tubes and a concentration range of test compounds between 1 x 10"5 M and 3 x 10"9 M (or 3 x l0"n M).
The IC5o values and Hill slopes for competition binding data were obtained using nonlinear four-parametric curve fitting method.
The exemplified compounds of the present invention have activities in the above binding assay of less than 20 micromolar, more particular compound have activities of less than 1 micromolar, and further particular compounds have activities of less than 200 nanomolar IC50.
TABLE 6
Example # IC50 (nM) Example # IC50 (nM)
1.1 177 27 80
1 60 28 81
2 760 29 150
3 60 30 53
4 37 31 360
5 19 32 123
6 20 33 42
7 38 34 22
8 3810 35 1430
9 32 36 28
10 64 37 76
11 200 38 163
12 13 39 99
13 1660 40 81
14 25 41 131
15 37 42 87
16 35 43 68
17 44 44 410
18 64 45 160
19 55 46 1000
20 1200 47 800
21 633 48 409
22 1 12 49 746
23 116 50 1240
24 58 51 157
25 25 52 177
26 64 53 789 482 84 107
6600 85 71
215 86 85
200 87 19
169 88 23
195 89 52
345 90 494
102 91 121
200 92 220
62 93 84
487 94 630
121 95 4040
85 96 443
77 97 4640
143 98 155
56 99 223
180 100 108
176 101 1810
825 102 154
154 103 260
350 104 15
45 105 53
45 106 144
182 107 5130
270 108 190
154 109 73
431 110 525
245 111 646
46 112 145
146 113 82 114 180 138 670
115 244 139 1200
116 160 140 260
117 71 141 200
118 190 142 120
119 3200 143 3000
120 2900 144 167
121 152 145 146
122 70 146 254
123 7000 147 7000
124 24% at 10 μΜ 148 26
125 465 149 165
126 58 150 98
127 1090 151 457
128 37% at 10 μΜ 152 149
129 105 153 294
130 5300 154 70
131 6500 155 2870
132 170 156 79
133 1640 157 71
134 240 158 1060
136 347 159 544
137 104 160 26% at 10 μΜ
Cyclic AMP Accumulation Assay
An in vitro functional assay measuring the changes in the intracellular cyclic adenosine 3 ',5 '-monophosphate (cyclic AMP, or also called as cAMP) level following either stimulation or activation of CXCR3-A receptor was used to demonstrate the antagonistic functionality of the selected compounds.
Cyclic AMP is one of the most important intracellular second messenger molecules whose level is regulated principally by the G-protein coupled adenylyl cyclase effector enzyme located in the inner surface of the cellular plasma membrane. Receptor dependent, G-protein mediated changes in the cyclic AMP concentration elicit then complex regulatory processes within the cell such as activation of multiple protein kinases and phospholipases, generation of inositol triphosphate and transient rise in the intracellular calcium ion (Ca2+) concentration, ion channel gating, effects on different gene transcriptions.
Upon agonist stimulation, CXCR3-A receptor activates the pertussis toxin (PTX) sensitive G- proteins of the Gi class that mediates a reduction in the intracellular cAMP levels, an increase in the intracellular Ca2+ mobilization and actin polymerization, that finally lead to cytoskeletal rearrangement and directed cell migration (chemotaxis).[Sauty A et al, 2001. J. Immunol. 167: 7084-7093.]
Cyclic AMP accumulation assay was performed with a homogeneous time-resolved fluorescence (HTRF) cAMP femto 2 kit from CisBio International. The measurement was basically carried out by following the manufacturer's instructions.
Since CXCR3-A receptor is coupled to Gi-protein, thus an agonist activation of the receptor will lead to a decrease in the intracellular cAMP level [Crosignani S. et al, 2010. Bioorg. Med. Chem Letters, 20:3614-3617]. Therefore, the cells have to be preactivated by forskolin, a direct activator of the cell adenylyl cyclase enzyme, in order to reach a sufficient cellular basal cAMP level. The agonist induced decrease in cAMP level will be measured by an increase of the Fluorescence Resonance Energy Transfer signal, as the signal is inversely proportional to the concentration of cAMP in the cell.
For the assay, the adherent hr-CXCR3-Flp-In-CHO- IRES-Gai4qi4 cells (the same cell line as used for binding assay) were washed with Ca2+-Mg2+ free PBS and harvested by a short treatment with Acutase (Sigma, A6964). At a time point of 2 min after adding Acutase (3 ml/ T175 flask) 7 ml of culture medium was added to the detached cells. Cell suspension was collected and centrifuged at 1,700 rpm for 10 min. (Sigma 2-S table centrifuge). The resulting cell pellet was resuspended in PBS with Ca2+/Mg2+ (Invitrogen 14080-048) and subjecting to a second centrifugation step as above. The final cell pellet was resuspended in assay buffer (PBS with Ca2+/Mg2+, supplemented with fatty acid free BSA (Sigma A6003) at a final concentration of 1 mg/ml and with the phosphodiesterase inhibitor Rolipram (Calbiochem 557330) at a final concentration of 10 μΜ. Cells were transferred to a 96- well microplate (Costar 3694, Half Area flat bottom, non-treated, black polystyrene plate) at a density of 16,000 cells/well.
The cells were incubated in the presence of different concentrations of antagonist compounds (within the range of 10μΜ and 0.1 nM) for 10 min at room temperature (R.T.) under continuous shaking the microplate in a plate shaker (Heidolph Titramax 100, at 600 rpm). The final concentration of DMSO in reaction mixture was 0.1 %. Then CXCLIO at a final concentration of 20 nM was added and the cells were further incubated for 10 min at R.T., as above. After that forskolin (Sigma F-6886) at 1 μΜ final concentration was added and an additional incubation period (30 min, R.T., shaking) followed. The final reaction volume was 40 μΐ. The reaction was stopped by adding the lysis buffer containing the HTRF reagents.
Plates were then incubated for 60 min at R.T. under shaking, and time-resolved FRET signals were measured after excitation at 337 nm. Both the emission signal from the europium cryptate- labelled anti-cAMP antibody (620 nm) and the FRET signal resulting from the labelled cAMP-d2 (665 nm) were recorded using a RubyStar instrument (BMG Labtechnologies).
The results were calculated as a fluorescence ratio (Em.665 nm/Em.620 nm) x 10000 and were analysed by calculating the Delta F value which corresponded to the following formula :
Delta F = ( Standard or Sample Ratio - Negative Control Ratio)/ (Negative Control Ratio) x 100. The negative control corresponded to the background signal obtained with the cryptate conjugate alone. The compounds tested in the above functional cAMP assay displayed an IC50 value of less than 2 micromolar and particularly less than 20 nanomolar.
Formulation Examples
(1) Tablets
The ingredients below are mixed by an ordinary method and compressed by using a conventional apparatus. Compound of Example 1 30 mg
Crystalline cellulose 60 mg
Corn starch 100 mg
Lactose 200 mg
Magnesium stearate 4 mg
(2) Soft capsules
The ingredients below are mixed by an ordinary method and filled in soft capsules.
(1) Parenteral preparations
The ingredients below are mixed by an ordinary method to prepare injections contained a 1 ml ampoule.
The compounds of the present invention have CXCR3 inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of a CXCR3 receptor mediated disease or disorder, especially of a disease or disorder selected from the group consisting of COPD, psoriasis, graft/transplant rejection, ophthalmological disease, celiac disease, inflammatory bowel disease (IBD), type 1 diabetes, myasthenia gravis (MG), multiple sclerosis (MS) and other neuroinflammatory diseases, lupus, rheumatoid arthritis (RA) or lichen planus.

Claims

Claims
1. A compound of formula 1
- wherein
R represents hydrogen or C i .4 alkyl group;
1 represents a group selected from the group consisting
- wherein R2 represents hydrogen or CM alkyl group;
R3 represents hydrogen, halogen, CF3, CN or Ci-4 alkyl; and
R4 represents hydrogen, halogen or C1-4 alkyl;
a = 0, 1 or 2; b = 0, 1, 2 or 3, c = 1 , 2 or 3, and
RA, RB, RC and RD represent independently from each other H or C].4 alkyl;
X represents a C2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a heteroatom selected from O and S, or -CH(CH2)CH-;
Y represents hydrogen, halogen, Ci-4 alkyl, C1-4 alkoxy or Ci- hydroxyalkyl;
Z represents a Ci-4 aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, N and N(CH3) or represents a C2-4 aliphatic hydrocarbon bridge fused with a C3-6 cycloalkyl ring optionally containing one or more double bond or with a phenyl ring or represents a C1.4 aliphatic hydrocarbon bridge substituted with a spiro C3.6 cycloalkyl ring optionally containing one or more double bond;
or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
2. A compound of formula 1 according to claim 1, wherein
represents hydrogen or Q. alkyl;
represents a group selected from the group consisting of
- wherein R2 represents hydrogen or Ci-4 alkyl;
R3 represents hydrogen, halogen, CF3, CN or C 1.4 alkyl; and
R4 represents hydrogen, halogen or Ci-4 alkyl;
a = 0 or I; b = 0, 1 or 2, c = I, 2 or 3; and
COOR
(CRaRb)b (CRcRd)c
(CH2)a
I represents a cycloalkane carboxylic acid or ester thereof, selected from the group consisting of
- wherein R° and Rd represent independently from each other H or C1-4 alkyl;
X represents -0-CH2-, -S-CH2-, -CH=CH-, -CH2-CH2-, -C≡C- or cyclopropandiyl; Y represents hydrogen, halogen; CM alkyl, C1-4 alkoxy or C1-4 hydroxyalkyl;
Z represents a Ci-4 aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, N and N(CH3) or represents a C2-4 aliphatic hydrocarbon bridge fused with a C3.6 cycloalkyl ring optionally containing one or more double bond or with a phenyl ring or represents a C 1.4 aliphatic hydrocarbon bridge substituted with a spiro C3-6 cycloalkyl ring optionally containing one or more double bond;
or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
3. A compound according to claim 1 or 2, wherein R represents hydrogen, or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
4. A compound according to any of claims 1 to 3, wherein R1 represents a group selected from the group consisting of
R3 represents CI, F, CF3, CN, methyl or ethyl
R4 represents hydrogen, CI, F or methyl;
or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
5. A compound according to any of claims 1 to 4, wherein Rl represents a group selected from the group consisting of
wherein R2 represents methyl or ethyl; and
R4 represents hydrogen, CI or F;
or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
6. A compound according to any of claims 1 to 5, wherein R1 represents a group selected from the group consisting of
or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
7. A compound according to any of claims 1 to 6, wherein X represents -O-CH2-, -S-
CH2- or -CH2-CH2-, or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
8. A compound according to any of claims 1 to 7, wherein Y represents hydrogen, CI, F, methyl, ethyl, methoxy or -CH2-OH; or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
9. A compound according to any of claims 1 to 8, wherein Y represents ethyl or methoxy; or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
A compound according to any of claims 1 to 9, wherein Z represents -(CH2)2-, - -CH2-0-, -CH2-S-, -CH2-N(CH3)-, -CH=CH-N(CH3)-, -N=CH-N(CH3)-,
cyclopropandiyl,
or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
1 1. A compound according to any of claims 1 to 10, wherein Z represents -(CH2)2- or -CH -N(CH3)-; or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
12. A compound of formula 1 according to claim 1, wherein
R represents hydrogen, methyl or ethyl;
1 represents a group selected from the group consisting of
- wherein R2 represents hydrogen methyl or ethyl;
R3 represents hydrogen, chloro, fluoro, CF3, CN, methyl or ethyl; and R4 represents hydrogen, chloro, fluoro, methyl or ethyl;
a = 0 or 1 ; b = 0, 1 or 2, c = 1, 2 or 3; and
COOR
(CRaRb). (CRcRd)c
represents a c cloalkane carboxylic acid or ester thereof, selected from the group consisting of
wherein Rc and R represent independently from each other H or methyl or ethyl;
X represents -0-CH2-, -S-CH2-, -CH=CH-, -CH2-CH2-, -C≡C- or cyclopropandiyl;
Y represents chloro, fluoro, methyl, ethyl, methoxy or -CH2-OH;
Z represents -(CH2)2-, -(CH2)3-, -CH2-0-, -CH2-S-, -CH2-N(CH3)-, -CH=CH-N(CH3)-,
N=CH-N(CH3)-, CH(CH2)CH-, , or
or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
13. A compound according to any of claims 1 to 12 selected from the group consisting of tra«5-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid ethyl ester
tro«i-4-[([l-(2,3-Dihydro-l-benzofuran-5-yl)ethyl] {4-[2-(2,5-dioxo-pyrrolidin-l-yl)ethoxy]-3- methoxybenzyl}amino)methyl]-cyclohexanecarboxylic acid
c^-4-[([l-(2,3-Dihydro- l -benzofuran-5-yl)ethyl] {4-[2-(2,5-dioxo-pyrrolidin-l -yl)ethoxy]-3- methoxybenzyl}amino)methyl]-cyclohexanecarboxylic acid
traHs-4-[([(i?)-l-(2,3-Dihydro-benzofe
3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
ira«j'-4-[([(5)- l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- l-yl)-ethoxy]- 3 -methoxy-benzyl } -amino)-methyl] -cyclohexanecarboxylic acid
trara-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy- benzyl}-amino)-methyl]cyclohexanecarboxylic acid trara-4-[([(^)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyiTolidin-l -yl)-ethoxy]-3-methoxy benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([(1S -l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methyl- benzyl } -amino)-methyl]-cyclohexanecarboxylic acid
d5-4-[([(5)-l -(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methyl- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trans-4-[([(R)- 1 -(4-Chloro-phenyl)-ethyl]- {4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy]-3-methyl- benzyl } -amino)-methyl] -cyclohexanecarboxylic acid
tra«5-4-[((5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyiTolidin-l-yl)-ethoxy]-3-methoxy-benzyl}- amino)-methyl]-cyclohexanecarboxylic acid
ira«5-4-[((( ? -5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy- benzyl }-amino)-methyl] -cyclohexanecarboxylic acid
traw-4-[(( S)-5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy- benzyl } -amino)-methyl] -cyclohexanecarboxylic acid
cz'5'-4-[((5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3-methoxy-benzyl}- amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[(((5)-4,5-Dichloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy- benzyl }-amino)-methyl] -cyclohexanecarboxylic acid hydrochloride
trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,4-dioxo-thiazolidin-3-yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
ir ra-4-({ {3-Chloro-4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-benzyl}-[l -(2,3-dihydro- benzofuran-5 -y l)-ethyl] -amino } -methyl)-cyclohexanecarboxylic acid
trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tra« -4-[([l-(2,3-Dihydro-benzofuran-5-yl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl] -cyclohexanecarboxylic acid
trora-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,4-dioxo-oxazolidin-3-yl)-ethoxy]-3- methoxy-benzyl }-amino)-methyl] -cyclohexanecarboxylic acid
trara-4-[((5-Chloro-indan-l-yl)-{3-chloro-4-[2-(3-rnethyl-2,5-dioxo-imidazolidin-l-yl)-ethoxy]- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trans - - { [ { 3 -Chloro-4- [2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy] -benzyl } -(5 -chloro-indan- 1 -yl)- amino] -methyl } -cyclohexanecarboxylic acid
trara-4-({ {3-Chloro-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l-yl)-ethoxy]-benzyl}-[l-(2,3- dihydro-benzofuran-5-yl)-ethyl]-amino}-methyl)-cyclohexanecarboxylic acid
trara-4-({{3-Chloro-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l -yl)-ethoxy]-benzyl}-[(S)-l-(4- chloro-phenyl)-ethyl]-amino}-methyl)-cyclohexanecarboxylic acid
trans A- [((5-Chloro-indan- 1 -yl)- {4- [2-(2,4-dioxo-thiazolidin-3 -yl)-ethoxy] -3 -methoxy-benzyl } - amino)-methyl]-cyclohexanecarboxylic acid
tram-4-[([l-(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl } -amino)-methyl] -cyclohexanecarboxylic acid
trara-4-[([(5)-l-(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
irara-4-[([(i?)-l-(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
/rara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-propyl]-{3-methoxy-4-[2-(3-methyl-2,5-dioxo- imidazolidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tr n5-4-[((5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3-methyl-benzyl}- amino)-methyl]-cyclohexanecarboxylic acid
tra«5-4-[(((S)-5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methyl-benzyl}- amino)-methyl]-cyclohexanecarboxylic acid
trora-4-[(((i?)-5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methyl-benzyl}- amino)-methyl]-cyclohexanecarboxylic acid
trara-4-({ {3-Chloro-4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-benzyl}-[(S)-l-(4-chloro-phenyl)- ethyl] -amino }-methyl)-cyclohexanecarboxylic acid
trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,4-dioxo-thiazolidin-3-yl)-ethoxy]-3- methyl-benzyl } -amino)-methyl] -cyclohexanecarboxylic acid
tra«5,-4-[([(5 -l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,4-dioxo-thiazolidin-3-yl)-ethoxy]-3-methoxy- benzyl } -amino)-methyl] -cyclohexanecarboxylic acid
trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[(E)-3-(2,5-dioxo-pyn-olidin-l -yl)- propenyl]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid tra« -[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,4-dioxo-oxazolidin-3-yl)-ethoxy]-3-methoxy- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tra«s-4-[([(S) -(4-Chloro-phenyl)-e
pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tra«5-4-[([l -(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,6-dioxo-piperidin-l-yl)-ethoxy]-3- methoxy-benzyl }-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{3-methyl-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l - yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[3-(2,5-dioxo-pyrrolidin-l -yl)-propyl]-3- methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
3-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl } -amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[((5-Chloro-6-methyl-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy- benzyl } -amino)-methy 1] -cyclohexanecarboxylic aci d
trara-4-[((5-Chloro-4-methyl-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
ira«s-4-[((5-Chloro-indan-l-yl)-{4-[3-(2,5-dioxo-pyrrolidin-l-yl)-propyl]-3-methoxy-benzyl}- amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[(((i?)-5-Chloro-indan-l-yl)-{4-[3-(2,5-dioxo-pyrrolidin-l-yl)-propyl]-3-methoxy- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
irara-4-[(((5)-5-Chloro-indan-l-yl)-{4-[3-(2,5-dioxo-pyrrolidin-l-yl)-propyl]-3-methoxy- benzyl } -amino)-methyl]-cyclohexanecarboxylic acid
trans- -({ {3-Chloro-4-[3-(2,5-dioxo-pyrrolidin-l -yl)-propyl]-benzyl}-[l -(2,3-dihydro- benzofuran-5-yl)-ethyl]-amino}-methyl)-cyclohexanecarboxylic acid
trara-4-[((5-Chloro-indan-l-yl)-{3-methoxy-4-[2-(3-methyl-2,6-dioxo-3,6-dihydro-2H- pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyiTolidin-l-ylmethyl)- cyclopropyl]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[((5-Chloro-indan-l-yl)-{3-methoxy-4-[3-(3-methyl-2,5-dioxo-imidazolidin-l-yl)- propyl]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{3-methoxy-4-[3-(3-methyl-2,5-dioxo-imidazolidin-l- yl)-propyl]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tra«5-4-[((5-Chloro-indan-l-yl)-{3-methoxy-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l-yl)- ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trans A- [([(5)- 1 -(4-Chloro-phenyl)-ethyl] - { 3 -methoxy-4- [2-(3 -methyl -2,5-dioxo-imidazolidin- 1 - yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[3-(2,5-dioxo-pyrrolidin-l-yl)-propyl]-3-methyl- benzyl }-amino)-methyl]-cyclohexanecarboxylic acid
tra«5-4-[([(S)-l-(4-Chloro-phenyl)-ethyl]-{4-[3-(2,5-dioxo-pyrrolidin-l-yl)-prop-l-ynyl]-3- methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tr ra-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[3-(2,5-dioxo-pyrrolidin-l-yl)-propyl]-3-methoxy- benzyl }-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[((5-Chloro-indan-l-yl)-{3-methyl-4-[2-(3-methyl-2,5-dioxo-imidazolidin- l -yl)-ethoxy]- benzyl }-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{3-methyl-4-[2-(3-methyl-2,6-dioxo-3,6-dihydro-2H- pyrimidin- 1 -yl)-ethoxy]-benzyl} -amino)-methyl]-cyclohexanecarboxylic acid
ira«s-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methoxy-4-[2-(3-methyl-2,6-dioxo-3,6- dihydro-2H-pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[([l-(2,3-Dihydro-benzofliran-5-yl)-ethyl]-{3-methyl-4-[2-(3-methyl-2,6-dioxo-3,6- dihydro-2H-pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid irara-4-[([l-(4-Cyano-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3-methyl- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([l-(4-Cyano-phenyl)-ethyl]-{3-methoxy-4-[2-(3-methyl-2,6-dioxo-3,6-dihydro-2H- pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
traw-4-[([l-(4-Chloro-phenyl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([l-(4-Chloro-phenyl)-propyl]-{3-methyl-4-[2-(3-methyl-2,6-dioxo-3,6-dihydro-2H- pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([l-(4-Chloro-phenyl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methyl- benzyl }-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-propyl]-{4-[3-(2,5-dioxo-pyrrolidin-l-yl)-propyl]-3- methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([l-(4-Chloro-phenyl)-propyl]-{3-methoxy-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l- yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([l-(4-Chloro-phenyl)-propyl]-{3-methoxy-4-[2-(3-methyl-2,6-dioxo-3,6-dihydro-2H- pyri midin- 1 -yl)-ethoxy] -benzyl } -amino)-methyl]-cyclohexanecarboxylic acid
irora-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methyl-benzyl } -amino)-methyl] -cyclohexanecarboxylic acid
trara-4-[([l-(4-Chloro-phenyl)-propyl]-{3-methyl-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l-yl)- ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tra«5'-4-[(((5)-5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-ethyl-benzyl}- amino)-methyl]-cyclohexanecarboxylic acid
tra«5-4-[(((S)-5-Chloro-indan-l -yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-fluoro-benzyl}- amino)-methyl]-cyclohexanecarboxylic acid
/rara-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-fluoro- benzy 1 } -amino)-methyl]-cyclohexanecarboxy lie acid
ira«s-4-[(((S -5,6-Dichloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy- benzyl }-amino)-methyl]-cyclohexanecarboxylic acid
traw-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-ethyl- benzyl }-amino)-methyl] -cyclohexanecarboxylic acid
tra 7j'-4-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- ethyl -benzyl } -amino)-methyl] -cyclohexanecarboxy 1 ic acid
/rara-4-[([l-(3,4-Dichloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tran5-4-[([l-(3,4-Dichloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methyl- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-benzyl}- amino)-methyl]-cyclohexanecarboxylic acid
tra«5-4-[([l-(3,4-Dichloro-phenyl)-ethyl]-{3-methyl-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l- yl)-ethoxy]-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-({{4-[2-(2,5-Dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-[l-(4-ethyl-phenyl)- ethyl] -amino } -methyl)-cyclohexanecarboxylic acid
tram-4-[([l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl } -amino)-methyl] -cyclohexanecarboxylic acid
tra«i-4-{[{4-[2-(2,5-Dioxo-pyrrolidin- l-yl)-ethoxy]-3-methyl-benzyl}-(l-p-tolyl-ethyl)-amino]- methyl}-cyclohexanecarboxylic acid
tra«5-4-{[{4-[2-(2,5-Dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-(l-p-tolyl-ethyl)- amino] -methyl} -cyclohexanecarboxylic acid
traw-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- hydroxymethyl-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tra«5-4-[(((S)-4,5-Dichloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-ethyl- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethylsulfanyl]-3- methoxy-benzyl}-amino)-rnethyl]-cyclohexanecarboxylic acid
tra«5-4-[(((S)-5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethylsulfanyl]-3-methoxy- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tram-4-[([l -(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-ethyl- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
trara-4-[([(i?)-l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-] -yl)-ethoxy]-3- ethyl-benzyl }-amino)-methyl]-cyclohexanecarboxylic acid
irara-4-[([(S)-l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- ethyl-benzyl }-amino)-methyl] -cyclohexanecarboxylic acid
tr ra-4-[([l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- fluoro-benzyl } -amino)-methyl] -cyclohexanecarboxylic acid
/r<3«5-4-[((4-Chloro-5-fluoro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy- benzyl }-amino)-methyl] -cyclohexanecarboxylic acid
irara-4-[((6-Chloro-5-fluoro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3-methoxy- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
tra«5-4-[((6-Chloro-5-fluoro-indan- 1 -yl)-{4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy]-3-ethyl- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid trara-4-[((4-Chloro-5-fluoro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-ethyl- benzyl } -amino)-methyl]-cyclohexanecarboxylic acid
irara-4-[((6-Chloro-5-fluoro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-fluoro- benzyl }-amino)-methyl]-cyclohexanecarboxylic acid
ir «5-4-[((5-Chloro-6-fluoro-indan- l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3-methoxy- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
(i ?,i/?)-3-[([(5)-l -(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid
(/5',55)-3-[([(5 -l -(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid
(i/?,i5)-3-[([(5)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl } -amino)-methyl] -cyclopentanecarboxylic acid
(75,i ?)-3-[([(5)-l -(4-Chloro-phenyl)-ethyl]-{4 2-(2,5-dioxo-pyrrolidin- l -yl^
methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid
(i^iS)-3-[([(i?)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid
(77?,5i?)-3-[([(i?)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid
(i/?,3/?)-3-[([(5)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid
(75,,5 ?)-3-[([(S)-l -(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid
(//?,55)-3-[([(5)- l -(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)- ethoxy] -3 -methoxy-benzyl } -amino)-methyl]-cyclopentanecarboxylic acid
(75,3/?)-3-[([(i?)- l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)- ethoxy] -3 -methoxy-benzyl } -amino)-methyl] -cyclopentanecarboxylic acid
(/5,,35')-3-[([(^)-l -(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- l-yl)- ethoxy] -3 -methoxy-benzyl } -amino)-methyl] -cyclopentanecarboxylic acid
(IS, 3S)-3-[([(S)- 1 -(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)- ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclopentanecarboxylic acid (7^2i?)-2-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]- 3-methoxy-benzyl}-amino)-methyl]-cyclopropanecarboxylic acid ethyl ester
(1R, 2R)-2-[([ 1 -(2,3-Dihydro-benzoftiran-5-yl)-ethyl]- {4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy]- 3-methoxy-benzyl}-amino)-methyl]-cyclopropanecarboxylic acid
(7S,,2i?)-2-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- l-yl)-ethoxy]- 3-methoxy-benzyl}-amino)-methyl]-cyclopropanecarboxylic acid ethyl ester
(75',2/?)-2-[([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]- 3-methoxy-benzyl}-amino)-methyl]-cyclopropanecarboxylic acid
(i^5^)-3-[([l-(4-Chloro-phenyl)-propyl]-{3-methyl-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l- yl)-ethoxy]-benzyl}-amino)-methyl]-2,2-dimethyl-cyclopropanecarboxylic acid
(i5',5S)-3-[([l-(4-Chloro-phenyl)-propyl]-{3-methoxy-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l - yl)-ethoxy]-benzyl}-amino)-methyl]-2,2-dimethyl-cyclopropanecarboxylic acid
(i5, )5S)-3-[([l -(4-Chloro-phenyl)^ropyl]-{4-[2-(2,5-dioxo-pyrrolidin- l-yl)-ethoxy]-3-methoxy- benzyl }-amino)-methyl]-2,2-dimethyl-cyclopropanecarboxylic acid
(7i?,5i?)-3-[([l -(4-Chloro-phenyl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin- l -yl)-ethoxy]-3-methyl- benzyl}-amino)-methyl]-2,2-dimethyl-cyclopropanecarboxylic acid
l -[((5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-amino)- methyl] -cyclopropanecarboxylic acid
ira«5,-3-([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methoxy-4-[2-(3-methyl-2,6-dioxo-3,6- dihydro-2H-pyrimidin-l-yl)-ethoxy] -benzyl }-amino)-cyclobutanecarboxylic acid
c 5-3-([l -(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methoxy-4-[2-(3-methyl-2,6-dioxo-3,6- dihydro-2H-pyrimidin- 1 -yl)-ethoxy] -benzyl } -ami no)-cyclobutanecarboxylic acid
cw-3-([( ?)-l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methoxy-4-[2-(3-methyl-2,6-dioxo-3,6- dihydro-2H-pyrimidin-l-yl)-ethoxy] -benzyl }-amino)-cyclobutanecarboxylic acid
c«-3-([(5)-l -(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methoxy-4-[2-(3-methyl-2,6-dioxo-3,6- dihydro-2H-pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-cyclobutanecarboxylic acid
trara-3-([l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methyl-benzyl}-amino)-cyclobutanecarboxylic acid
cis-3-([ 1 -(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy]-3-methyl- benzyl }-amino)-cyclobutanecarboxylic acid 3-([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl}-amino)-cyclobutanecarboxylic acid
3-((5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3-tnethoxy-benzyl}-amino)- cyclobutanecarboxylic acid
trara-3-([(i?)-l-(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methyl-benzyl}-amino)-cyclobutanecarboxylic acid
m-3-([(7?)-l-(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methyl-benzyl}-amino)-cyclobutanecarboxylic acid
trara-3-([(5)-l-(4-Chloro-3-methyl-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3 methyl-benzyl}-amino)-cyclobutanecarboxylic acid
cis-3 -([(S 1 -(4-Chloro-3 -methyl-phenyl)-ethyl] - { 4- [2-(2,5 -dioxo-pyrrolidin- 1 -yl)-ethoxy] -3 - methyl-benzyl}-amino)-cyclobutanecarboxylic acid
cw-3-([(i?)-l-(4-Chloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methyl- benzyl } -amino)-cyclobutanecarboxy 1 ic acid
cw-3-((5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3-methyl-benzyl}- amino)-cyclobutanecarboxylic acid
c/5-3-([l-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-{3-methyl-4-[2-(3-methyl-2,6-dioxo-3,6-dihydro- 2H-pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-cyclobutanecarboxylic acid
cw-3-([l-(2,3-Dihydro-benzofuran-5-yl)-propyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methyl-benzyl}-amino)-cyclobutanecarboxylic acid
cw-3-([( ?)-l-(4-Chloro-phenyl)-ethyl]-{3-methyl-4-[2-(3-methyl-2,6-dioxo-3,6-dihydro-2H- pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-cyclobutanecarboxylic acid
m-3-([l-(3,4-Dichloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy- benzyl } -amino)-cyclobutanecarboxy lie acid
m-3-([l-(3,4-Dichloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methyl- benzyl }-amino)-cyclobutanecarboxylic acid
cis-3 -([ 1 -(3 ,4-Dichloro-phenyl)-ethy 1] - {4- [2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy] -3 -ethyl- benzyl }-amino)-cyclobutanecarboxylic acid
cis-3 -([1 -(4-Chloro-3 -fluoro-phenyl)-ethyl] - {4- [2-(2,5-dioxo-pyrrolidin- 1 -yl)-ethoxy] -3 -ethyl - benzyl }-amino)-cyclobutanecarboxy lie acid c 5,-3-([l -(3,4-Dichloro-phenyl)-propyl]-{4-[2-(2,5-dioxo-pyrroHdin-l-yl)-ethoxy]-3-methoxy- benzyl } -amino)-cyclobutanecarboxylic acid
m-3-([l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- methoxy-benzyl}-amino)-cyclobutanecarboxylic acid
cw-3-([(/?)-l-(4-Chloro-phenyl)-ethyl]-{4-[3-(2,5-dioxo-pyrrolidin-l-yl)-propyl]-3-methyl- benzyl } -amino)-cyclobutanecarboxylic acid
trara-4-{[{4-[2-(2,5-Dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-(l-indan-5-yl-ethyl)- amino]-methyl}-cyclohexanecarboxylic acid
tra«5-4-[((l-Indan-5-yl-ethyl)-{3-methoxy-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l -yl)-ethoxy]- benzyl}-amino)-methyl]-cyclohexanecarboxylic acid
-4-[(((S)-5-Chloro-indan-l-yl)-{4-[2-(2,4-dioxo-3-aza-bicyclo[3.1.0]hex-3-yl)-ethoxy]-3- methoxy-benzyl } -arnino)-methyl]-cyclohexanecarboxylic acid
4-[(((S)-5-Chloro-indan-l -yl)-{4-[2-(7,9-dioxo-8-aza-spiro[4.5]dec-8-yl)-ethoxy]-3-niethoxy- benzyl }-amino)-methyl]-cyclohexanecarboxylic acid
traoi-4-[(((S)-5-Chloro-4-fluoro-indan- l-yl)-{4-[2-(2,5-dioxo-pyrrolidin- l-yl)-ethoxy]-3- methoxy-benzyl } -amino)-methyl]-cyclohexanecarboxylic acid
traos-4-[(((S)-5-Chloro-4-fluoro-indan- l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-ethyl- benzyl }-amino)-methyl]-cyclohexanecarboxylic acid
cis-3 -([(R)- 1 -(4-Chloro-3 -fluoro-phenyl)-ethyl]- {4- [2-(2,5-dioxo-pyrrol idin- 1 -yl)-ethoxy] -3 - methoxy-benzyl}-amino)-cyclobutanecarboxylic acid
c«-3-([(R)-l-(4-Chloro-3-fluoro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3- ethyl-benzyl }-amino)-cyclobutanecarboxylic acid
cw-3-([(R)-l-(3,4-Dichloro-phenyl)-ethyl]-{4-[2-(2,5-dioxo-pyrrolidin-l -yl)-ethoxy]-3-methoxy- benzyl }-amino)-cyclobutanecarboxylic acid
c«-3-([(R)-l-(4-Chloro-phenyl)-ethyl]-{3-methyl-4-[2-(3-methyl-2,5-dioxo-imidazolidin-l-yl)- ethoxy] -benzyl } -amino)-cyclobutanecarboxylic acid
/ra«5-4-({{4-[2-(2,5-Dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}-[l-(4-trifluoromethyl- phenyl)-ethyl]-amino}-methyl)-cyclohexanecarboxylic acid
tram-4-[(((S)-5-Chloro-indan-l -yl)-{4-[2-((3aS,7aR)-l,3-dioxo-l ,3,3a,4,7,7a-hexahydro- isoindol-2-yl)-ethoxy]-3-methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid;
hydrochloride trara-4-[(((S)-5-Chloro-indan-l-yl)-{4-[2-(l ,3-dioxo-l,3-dihydro-isoindol-2-yl)-ethoxy]-3- methoxy-benzyl}-amino)-methyl]-cyclohexanecarboxylic acid; hydrochloride
trara-4-[(((S)-5-Chloro-4-fluoro-indan-l-yl)-{3-methyl-4-[2-(3-methyl-2,5-dioxo-imidazolidin- 1 -yl)-ethoxy] -benzyl } -amino)-methyl] -cyclohexanecarboxy lie acid
3-[(((S)-5-Chloro-indan-l-yl)-{4-[2-(2,5-dioxo-pyrrolidin-l-yl)-ethoxy]-3-methoxy-benzyl}- amino)-methyl]-cyclobutanecarboxylic acid
cw-3-(((R)-l-Indan-5-yl-ethyl)-{3-methoxy-4-[2-(3-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin- l-yl)-ethoxy]-benzyl}-amino)-cyclobutanecarboxylic acid
trara-3-(((R)-l-Indan-5-yl-ethyl)-{3-methoxy-4-[2-(3-methyl-2,6-dioxo-3,6-dihydro-2H- pyrimidin-l-yl)-ethoxy]-benzyl}-amino)-cyclobutanecarboxylic acid
or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.
14. Process for the preparation of a compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer, comprising the steps of reductive amination of a benzaldehyde of formula 4
4
- wherein X, Y and Z have the meaning as defined in claim 1 - with a primary amine of formula 5
R— NH2
5
-wherein R has the meaning as defined in claim 1- reacting the obtained secondary amine of formula 2
2
with a formyl- or oxocycloalkane carboxylic acid ester of formula 3
3
-wherein R, Ra, Rb, Rc,Rd, b, and c have the meaning as defined in claim 1 and R' represents - CHO or =0 - and optionally hydrolyzing the obtained ester of formula 1.
15. A compound according to any of claims 1 to 13 or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer for use as a medicament.
16. A compound according to any of claims 1 to 13 or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer for use in the preventive and/or therapeutic treatment of a CXCR3 receptor mediated disease or disorder.
17. A compound according to claim 16 for use in the preventive and/or therapeutic treatment of a CXCR3 receptor mediated disease or disorder wherein the disease or disorder is selected from the group consisting of COPD, psoriasis, graft/transplant rejection, ophthalmological disease, celiac disease, inflammatory bowel disease (IBD), type 1 diabetes, myasthenia gravis (MG), multiple sclerosis (MS) and other neuroinflammatory diseases, lupus, rheumatoid arthritis (RA) or lichen planus.
18. Pharmaceutical compositions containing at least one compound according to any of claims 1 to 13 or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer and at least one pharmaceutically acceptable excipient.
19. Pharmaceutical composition according to claim 18 for use in the preventive and/or therapeutic treatment of a disease or disorder selected from the group consisting of COPD, psoriasis, graft/transplant rejection, ophthalmological disease, celiac disease, inflammatory bowel disease (IBD), type 1 diabetes, myasthenia gravis (MG), multiple sclerosis (MS) and other neuroinflammatory diseases, lupus, rheumatoid arthritis (RA) or lichen planus.
20. A compound of formula 4,
4
- wherein
X represents a C2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a heteroatom selected from O and S, or -CH(CH2)CH-;
Y represents hydrogen, halogen, Ci-4 alkyl, CM alkoxy or CM hydroxyalkyl;
Z represents a C aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, N and N(CH3) or represents a C2-4 aliphatic hydrocarbon bridge fused with a C3.6 cycloalkyl ring optionally containing one or more double bond or with a phenyl ring or represents a C aliphatic hydrocarbon bridge substituted with a spiro C3-6 cycloalkyl ring optionally containing one or more double bond.
21. A compound of formula 2
2
- wherein
R represents a group selected from the group consisting of
R3 represents hydrogen, halogen, CF3, CN or C
R4 represents hydrogen, halogen or CM alkyl;
X represents a C2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a heteroatom selected from O and S, or -CH(CH2)CH-;
Y represents hydrogen, halogen, CM alkyl, C alkoxy or C ,-4 hydroxyalkyl;
Z represents a CM aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, N and N(CH3) or represents a C2-4 aliphatic hydrocarbon bridge fused with a C3-6 cycloalkyl ring optionally containing one or more double bond or with a phenyl ring or represents a C M aliphatic hydrocarbon bridge substituted with a spiro C3-6 cycloalkyl ring optionally containing one or more double bond;
or a salt thereof.
22. Method of treating or preventing a CXCR3 receptor mediated disease or disorder comprising administering a pharmaceutically effective amount of one or more compounds according to any of claims 1 to 13 to a patient in need thereof.
23. Method according to claim 22 wherein the CXCR3 receptor mediated disease or is selected from the group consisting of COPD, psoriasis, graft/transplant rejection, ophthalmological disease, celiac disease, inflammatory bowel disease (IBD), type 1 diabetes, myasthenia gravis (MG), multiple sclerosis (MS) and other neuroinflammatory diseases, lupus, rheumatoid arthritis (RA) or lichen planus.
EP12806104.1A 2011-12-06 2012-12-03 Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists Active EP2787992B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12806104.1A EP2787992B1 (en) 2011-12-06 2012-12-03 Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11462023.0A EP2601950A1 (en) 2011-12-06 2011-12-06 Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
PCT/HU2012/000128 WO2013084013A1 (en) 2011-12-06 2012-12-03 Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists
EP12806104.1A EP2787992B1 (en) 2011-12-06 2012-12-03 Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists

Publications (2)

Publication Number Publication Date
EP2787992A1 true EP2787992A1 (en) 2014-10-15
EP2787992B1 EP2787992B1 (en) 2016-08-24

Family

ID=47429941

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11462023.0A Withdrawn EP2601950A1 (en) 2011-12-06 2011-12-06 Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
EP12806104.1A Active EP2787992B1 (en) 2011-12-06 2012-12-03 Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11462023.0A Withdrawn EP2601950A1 (en) 2011-12-06 2011-12-06 Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists

Country Status (17)

Country Link
US (1) US9073853B2 (en)
EP (2) EP2601950A1 (en)
JP (1) JP6133887B2 (en)
KR (1) KR20140098852A (en)
CN (1) CN103957905B (en)
AR (1) AR089087A1 (en)
AU (1) AU2012349866B2 (en)
BR (1) BR112014013590A2 (en)
CA (1) CA2857198A1 (en)
IL (1) IL232985A (en)
MX (1) MX359404B (en)
MY (1) MY168750A (en)
RU (1) RU2615993C2 (en)
SG (1) SG11201402980XA (en)
TW (1) TWI572590B (en)
UY (1) UY34489A (en)
WO (1) WO2013084013A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110731968A (en) * 2019-09-10 2020-01-31 南京鼓楼医院 ICOS+CXCR3+Application of regulatory T cells in preparation of severe pneumonia prevention medicine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58109455A (en) * 1981-11-20 1983-06-29 Kureha Chem Ind Co Ltd N-benzyl amino acid derivative and its preparation
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
EP1437344A4 (en) * 2001-09-28 2006-09-20 Takeda Pharmaceutical Benzene derivatives,process for preparing the same and use thereof
US20030225288A1 (en) 2002-04-12 2003-12-04 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US20040204455A1 (en) * 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
JP2007238489A (en) * 2006-03-07 2007-09-20 Kanagawa Acad Of Sci & Technol Chemiluminescent compound and labeling agent composed of the same
US20110034487A1 (en) 2008-01-22 2011-02-10 Amgen Inc. Cxcr3 antagonists
PE20091576A1 (en) 2008-02-19 2009-11-05 Sanofi Aventis DERIVATIVES OF 3- (AMIDO OR SULFAMIDE) -4- (SUBSTITUTED 4-AZINYL) BENZAMIDE AS INHIBITORS OF THE CxCR3 CHEMOKINE RECEPTOR

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013084013A1 *

Also Published As

Publication number Publication date
TWI572590B (en) 2017-03-01
IL232985A0 (en) 2014-07-31
RU2014127303A (en) 2016-02-20
US9073853B2 (en) 2015-07-07
RU2615993C2 (en) 2017-04-12
EP2787992B1 (en) 2016-08-24
BR112014013590A8 (en) 2017-06-13
KR20140098852A (en) 2014-08-08
AR089087A1 (en) 2014-07-30
JP2015500272A (en) 2015-01-05
CA2857198A1 (en) 2013-06-13
AU2012349866B2 (en) 2017-07-20
MY168750A (en) 2018-11-30
UY34489A (en) 2013-07-31
JP6133887B2 (en) 2017-05-24
AU2012349866A1 (en) 2014-07-03
TW201335137A (en) 2013-09-01
EP2601950A1 (en) 2013-06-12
MX2014006827A (en) 2014-08-01
CN103957905B (en) 2017-10-13
BR112014013590A2 (en) 2017-06-13
WO2013084013A1 (en) 2013-06-13
MX359404B (en) 2018-09-27
US20140288106A1 (en) 2014-09-25
CN103957905A (en) 2014-07-30
SG11201402980XA (en) 2014-07-30
IL232985A (en) 2017-02-28

Similar Documents

Publication Publication Date Title
US20110028405A1 (en) Sulfamides as zap-70 inhibitors
US10995101B2 (en) 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers
US6403626B1 (en) Benzimidazole derivatives
US6495583B1 (en) Benzimidazole derivatives
KR20190040990A (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of use thereof
JP2002510623A (en) Antidiabetic drugs
EA030962B1 (en) Substituted pyrimidine compounds and their use as syk inhibitors
CA2877184A1 (en) Lpar-substituted cyanopyrazole compounds
EP2787992B1 (en) Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists
EP2852578B1 (en) SUBSTITUTED ß-AMINO ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS
EP2801573A1 (en) Hydantoine derivatives as CD38 inhibitors
US9315493B2 (en) Phenylpyridine derivative and drug containing same
US20120122906A1 (en) Novel sulfonamide derivative and pharmaceutical product containing same
US20240076272A1 (en) Activators of Heme Regulated Inhibitor Kinase (HRI)
AU2003221394B2 (en) Novel pyridone derivative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140707

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17Q First examination report despatched

Effective date: 20150824

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160414

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 822430

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012022288

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160824

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 822430

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161124

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161125

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012022288

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161124

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26N No opposition filed

Effective date: 20170526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161231

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161231

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20121203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161203

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160824

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20181120

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20181114

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20191015

Year of fee payment: 8

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602012022288

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20191203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191203

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231